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ABSTRACT
Blood coagulation is a critical hemostatic process that must be properly regulated
to maintain the delicate balance between bleeding and clotting. Disorders of blood
coagulation can expose patients to the risk of either bleeding disorders or thrombotic
diseases. Coagulation diagnostics using whole blood is promising for the assessment of
the complexity of the coagulation system and for global measurements of hemostasis.
Despite the clinical values that existing whole blood coagulation tests have demon-
strated, these systems have significant limitations that compromise their potential
for point-of-care applications. Device miniaturization using micro-technology has the
potential to provide assays with low blood consumption and high accuracy. However,
the reported works either focused on developing tools for mechanistic study, or were
complicated to be implemented for point-of-care applications.
This thesis aimed to leverage advances in micro-technology and functional soft
materials to develop miniaturized devices for clot retraction force measurements, pro-
viding accurate and reliable blood coagulation assays with potentials for point-of-care
applications.
First, I designed a force-sensing device, named Miniaturized Hemoretractometer
(mHRM), based on image acquisition and analysis to measure the contraction force
generated during blood clotting. This clot retraction force served as an indicator
of coagulation functionality. I demonstrated that mHRM generated measurements
that were consistent with reported works, under various conditions such as different
temperatures and pro-/anti-coagulant treatments, which proved the efficacy of the
xiv
concept of using mHRM as a tool for blood coagulation diagnostics.
Acquiring electrical signals instead of images could vastly miniaturize the instru-
mentation of mHRM. However, integrating conductive materials into soft elastomer,
such as PDMS, was a challenge. To address this problem, I developed a method
to coat carbon nanotubes (CNTs) on PDMS surface from CNT solutions leveraging
capillary action. I demonstrated that the deposited CNT films had good uniformity
and piezoresistivity, making them strong candidate for the development of strain sen-
sors. This study contributed a novel and convenient method for solution-based CNT
deposition.
Finally, I applied this CNT deposition method into the design of mHRM and
developed a CNT-strain-sensor-based mHRM (CNT-mHRM). I investigated the pa-
rameters that affected the sensitivity of CNT-mHRM devices and demonstrated that
CNT-mHRM generated results that were consistent with image-analysis-based mea-
surements. The utility of CNT-mHRM was further demonstrated by showing its ca-
pability of differentiating blood samples under pro- and anti-coagulation treatments.
Thus, I have demonstrated the potential of CNT-mHRM devices as a practical point-
of-care tool for blood coagulation diagnostics.
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CHAPTER I
Introduction
This chapter is in part adapted from:
Li, Zida, Xiang Li, Brendan McCracken, Yue Shao, Kevin Ward, and
Jianping Fu. “A miniaturized hemoretractometer for blood clot retraction
testing.” Small 12, no. 29 (2016): 3926-3934.
Li, Xiang, Weiqiang Chen, Zida Li, Ling Li, Hongchen Gu, and Jianping
Fu. “Emerging microengineered tools for functional analysis and pheno-
typing of blood cells.” Trends in biotechnology 32, no. 11 (2014): 586-594.
1.1 Background
1.1.1 Physiology of blood coagulation
Blood coagulation is a critical hemostatic process involving an intricate interplay
between cellular (red blood cells, white blood cells, and platelets) and acellular com-
ponents (plasma proteins) of the blood [1, 2]. It is normally initiated when the blood
vessel is injured and the connective tissues (particularly collagen) underlying the en-
dothelial lining of the vessel are exposed to blood flow, leading to platelet adhesion
to connective tissues, activation, and aggregation, forming a plug at the site of vessel
injury [3]. In the meanwhile, vessel injury also exposes tissue factors in connective
1
tissues to different coagulation factors in the blood plasma, ultimately leading to a co-
agulation cascade. The coagulation cascade involves the cleavage of fibrinogen, which
then polymerizes into fibrin gel. Importantly, activated platelets bind and exert a
contractile force on fibrin strands and promote the formation of a highly crosslinked
fibrin network, which further strengthens the structural integrity of platelet plug,
leading to increased clot strength and its elastic modulus [4, 5].
Among the various cellular and acellular components involved in blood coagula-
tion, platelets, fibrinogen, and thrombin play particularly essential roles.
Platelets, or thrombocytes, are non-nucleated, discoid-shaped cell fragments, typ-
ically with a diameter of 2-4 µm and a thickness of about 0.5 µm [6]. They are gener-
ated when the cytoplasm of megakaryocytes in the bone marrow breaks up and enters
the circulation [7]. Binding to connective tissue collagen stimulates platelets to release
chemical agents, such as adenosine diphosphate and serotonin, leading to platelet ac-
tivation. Upon activation, platelets undergo multiple changes in metabolism, shape,
and surface proteins, which cause platelets to adhere to each other in a process called
platelet aggregation, generating platelet plugs to seal small vessel breaks. Acti-
vated platelets also experience actomyosin-mediated muscle-like contraction, which
improves the strength of platelet plugs and enhances the effectiveness in stopping
bleeding. Platelet contraction is the direct source of clot retraction observed in coag-
ulation assays.
Fibrinogen is a plasma glycoprotein composed of two trimers, with each composed
of α, β, and γ chains [8]. During blood clotting, fibrinogen is cleaved to form individ-
ual fibrin strands and two small polypeptides, which are derived from alpha and beta
chains. Individual fibrin strands polymerize to form fibrin network and provide the
scaffold of blood clots. Additionally, fibrin binds to platelets through platelets’ sur-
face membrane receptors. At the end of blood clotting, the fibrin network is broken
down in a process called fibrinolysis, primarily mediated by plasmin. Cross-linking
2
of fibrinogen leads to the viscoelasticity change of blood during clotting, which is
the foundation of thromboelastography-based blood coagulation assays [9] discussed
later.
Thrombin is a serine protease converted from plasma protein prothrombin in co-
agulation cascade. Thrombin catalyzes and stabilizes the formation of fibrin network
from fibrinogen [10]. In addition, thrombin activates several coagulation factors,
forming a positive feedback and promoting blood coagulation. Thrombin is also
an important activator of platelets. Therefore, comprised function of thrombin has
profound effect on blood coagulation. For example, heparin, a commonly used an-
ticoagulant, prevents blood coagulation by activating protein antithrombin, which
inhibits the activity of thrombin.
Besides these three participants, calcium is also essential to coagulation. Effective
activation of coagulation factors relies on the binding of these factors to cell sur-
faces. This surface binding is dependent on calcium and, therefore, sequestering of
calcium prevents blood from coagulating [11]. Though calcium concentration in the
plasma can never be low enough to cause clotting defect before other fatal conditions
occur, sequestering of calcium has been the mechanism of several commonly used
anticoagulants, such as citrate and ethylenediaminetetraacetic acid (EDTA).
Blood coagulation must be properly regulated to maintain the delicate balance
between bleeding and clotting. Disorders of blood coagulation can expose patients to
the risk of either bleeding disorder, such as hemophilia and Glanzmann’s thrombas-
thenia, or thrombotic diseases, such as heart attack, stroke, deep venous thrombosis,
pulmonary embolism, etc.[12]. Therefore, the ability to accurately determine the
hemostatic profile of a patient is of great importance for the diagnosis of clotting-
related diseases.
In addition, monitoring of coagulation functionality is critical in making clinical
decisions for many therapies, including hemostatic therapy [13], transfusion therapy
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[14], and anticoagulation therapy. For example, in perioperative care, rapid and ro-
bust reporting of hemostatic profile provides critical information for the decision on
anticoagulant dosage, which is important in minimizing the need of blood transfu-
sion. Another example is the treatment of thrombotic diseases with anticoagulation
therapy. Accurate profiling of coagulation functionality helps clinicians decide the op-
timal dosage of anticoagulant administration, reducing the risk of bleeding disorders
and other complications.
1.1.2 Assays for coagulation functionality
Coagulation diagnostics using whole blood samples has been proposed as an ef-
fective method for assessing the complexity of the coagulation system and for global
measurements of hemostasis. Compared to routine coagulation tests in the clinic
(such as prothrombin time or PT, activated partial thromboplastin time or aPTT, and
platelet count), whole-blood coagulation tests offer significant advantages of measur-
ing the whole clotting process, starting with fibrin formation and continuing through
to clot retraction and fibrinolysis, and allowing the plasmatic coagulation system to
interact with blood cells including platelets, thereby providing useful additional in-
formation on platelet function [15]. Among different whole blood coagulation tests,
viscoelastic hemostasis assays including thromboelastography (TEG) and rotational
thromboelastometry (ROTEM) have gained significant attention in the clinic [16]. In
principle, TEG and ROTEM measure the changes in the strength and elasticity of
whole blood upon clotting. For example, TEG consists of a rotating cup and a pin
which is connected to a rotation sensor. Blood sample is held in the cup and the pin
is submerged in the blood sample during the assay. When the blood starts clotting,
its viscoelasticity changes, leading the pin to rotate along with cup. The rotational
amplitude of the pin is recorded by the rotation sensor and reported for analysis of the
viscoelasticity change of the blood sample. Such viscoelastic hemostasis assays have
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been shown to provide critical information on the interactivity of the major phases
of clot formation and lysis and on the functional differences between different cellular
and acellular components of the blood for differentiating the mechanism(s) related to
clotting abnormalities [17].
Besides viscoelastic hemostasis assays, whole-blood clot retraction assays using
devices such as Hemodyne Hemostasis Analysis System (HAS, Hemodyne, Inc.) are
another method reported to provide important information on blood coagulation func-
tion, reporting on clot elastic modulus and platelet contractile force (or clot retraction
force) [18, 19]. In HAS, whole blood samples are confined between two plates (either
flat-flat or cone-cone surfaces), with the top plate attached to a strain-gauge trans-
ducer. Clotting of blood results in a downward force pulling the top plate, which is
directly measured in real time by the strain-gauge transducer. Using HAS, clot retrac-
tion force has been shown to be sensitive to platelet count, platelet metabolic status,
glycoprotein IIB/IIIa status, and the presence of antithrombin activities [18]. Im-
portantly, clinical applications of the HAS have demonstrated promising applications
of such whole blood clot retraction assays for rapid assessment of global hemostasis
[20–22] and the response to a variety of procoagulant and anticoagulant medications
[23–25].
Despite the clinical values that existing whole blood coagulation tests have demon-
strated through initial applications, such systems still have significant limitations in
terms of costly expense to make and repair, limited sample throughput, large foot-
print, and excessive sample size (> 0.3 mL) that can be problematic for repetitive
assays on pediatric patients, inter-assay variability, and significant user interventions,
rendering them suboptimal for point-of-care applications [26].
Device miniaturization based on emerging functional materials and micro/nano-
technology holds great potential to develop assays with low cost, low blood consump-
tion, and high accuracy, which are suitable for point-of-care application. Several
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works have been reported, and these works assessed either of the two important bio-
physical properties of blood clotting: viscoelasticity change and platelet contractile
force dynamics.
Similar as TEG and ROTEM, the principle of measuring viscoelasticity using
miniaturized devices is to apply actuation, commonly vibration, to blood samples
and monitor the response over time. For example, in a study based on oscillating
cantilever, the cantilever was actuated and the resultant oscillation of the cantilever
was dependent on the viscoelasticity of the blood samples that the cantilever was
merged in [27]. By monitoring the oscillation, blood viscoelasticity could be deduced.
Another study used actuated surface-attached posts that were deformed under mag-
netic field; this deformation was dependent on the stiffness of the blood sample,
which served as the measuring principle [28]. Similar concepts were also adopted in
the studies using capillary flows [29, 30].
Several methods were developed to measure platelet contractile force. For ex-
ample, traction force microscopy was employed to study the dynamic evolution of
platelet contractile force during platelet activation, where microbeads were incorpo-
rated into the surface of a compliant polymer substrate and platelets were allowed to
adhere and exert platelet contractile force on the substrate [31]. When the platelets
started contracting, displacements of beads were observed and recorded to deduce
the force field. Another successful cell traction force measurement tool, termed a
micropost force sensor, was also utilized to measure platelet contractile force [32].
Platelets were seeded on top of polydimethylsiloxane (PDMS) microposts pre-coated
with fibrinogen or fibronectin to facilitate platelet adhesion. Once platelets were
activated by addition of thrombin, deflections of the microposts were observed and
recorded to calculate platelet contractile force based on Euler–Bernoulli beam theory.
Variations of this method have been developed to study the effects of glycoprotein Ib
and von Willebrand factor (vWF) [33] and shear force [34] on platelet contraction.
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In another recent study, custom-built side-view atomic force microscopy (AFM) was
used to measure the platelet contractile force generated by single platelets bridging
the AFM cantilever and a substrate [35].
These reported micro-engineered tools have significantly improved measurement
accuracy and sensitivity to unprecedented levels. However, these tools were designed
primarily for mechanistic studies and thus are complicated and suboptimal for di-
rect clinical applications. Microengineered tools that are convenient for point-of-care
blood coagulation assays remains to be developed.
1.2 Thesis objectives and outline
This thesis aims to leverage the advances in micro-technology and functional soft
materials and develop a miniaturized device, named Miniaturized Hemoretractome-
ter (mHRM), for accurate and reliable blood coagulation assay with potentials for
point-of-care applications. In particular, I designed flexible beams with image anal-
ysis modules to measure the contraction force generated during blood clotting. This
clot retraction force served as an indicator of coagulation functionality. To equip
mHRM with real-time electrical readout, I developed a method to deposit piezoresis-
tive material, namely carbon nanotube, on soft elastomer PDMS. Using this deposi-
tion technique, I fabricated piezoresistor strain sensors on the beams in mHRM and
demonstrated its applicability.
The current chapter talks about the physiological background of blood coagu-
lation and the significance of effective assays. It also talks about the limitations
of existing assays, including conventional tools and emerging tools based on device
miniaturization. The overall objective of this thesis is then discussed.
Chapter 2 describes the design, characterization, and validation of mHRM that
is based on image analysis. Taking advantage of surface tension, this design adopted
two beams with protrusions to hang a blood drop. Such design ensured reproducible
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localization of blood samples after loading. Characterization was performed with fi-
nite element methods in COMSOL; the simulation model and results were discussed.
mHRM devices were validated by testing blood samples using pig blood samples
under varied conditions with known coagulation profiles, including different temper-
ature, with and without coagulation activator, and pro-/anti-coagulant treatment. A
comparison with standard tests TEG is also presented. Following these experimental
results, the outlook of clinical application is discussed in detail.
Though mHRM showed potential in clinical applications for point-of-care blood
coagulation testing, its data acquisition relied on image capturing and thus optical
instruments. Further democratization of mHRM required replacement of image cap-
turing with electrical signal acquisition in raw data collection, which could be achieved
with a specially designed integrated circuits. However, integrating electrical units in
PDMS has been a challenge.
Chapter 3 describes a method of depositing piezoresistive material, namely car-
bon nanotube (CNT), on PDMS surface. Micropillar arrays were fabricated on elastic
PDMS substrates and then the PDMS surfaces were treated by oxygen plasma to ren-
der them hydrophilic. After CNT solution was dispensed onto the PDMS substrate,
capillary force spread CNT solution evenly on the PDMS substrate. Water evapora-
tion left a uniform deposition of CNT on PDMS substrates. The morphology of CNT
is presented and the effect of CNT concentration and micropillar gap size on CNT
coating uniformity, film conductivity, and piezoresistivity are discussed.
Chapter 4 discusses an improved mHRM by implementing the CNT deposition
method into a new device design, named CNT-mHRM. In the new design, I adopted
a fixed protrusion and a thin PDMS beam to localize the blood sample, and deposited
CNT on the backside of PDMS beam to serve as the strain sensor. The design and
fabrication of the device is discussed, and the characterization of electro-mechanical
response is presented. The validity of the devices is demonstrated by the compari-
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son of test results with those from image analysis, and the utility of the devices is
demonstrated by showing CNT-mHRM’s capability of differentiating blood samples
with different coagulation profiles.
Chapter 5 summarizes this thesis work and discusses its potential application in
commercialization as well as in laboratory research. Potential directions for further
improvement on the device performance are also discussed.
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CHAPTER II
The imaging-based hemoretractometer for blood
clot retraction testing
This chapter is in part adapted from:
Li, Zida, Xiang Li, Brendan McCracken, Yue Shao, Kevin Ward, and
Jianping Fu. “A miniaturized hemoretractometer for blood clot retraction
testing.” Small 12, no. 29 (2016): 3926-3934.
2.1 Introduction
Blood coagulation is a critical hemostatic process that must be properly regulated
to maintain a delicate balance between bleeding and clotting. Disorders of blood co-
agulation can expose patients to the risk of either bleeding disorders or thrombotic
diseases. Coagulation diagnostics using whole blood is very promising for assessing
the complexity of the coagulation system and for global measurements of hemostasis.
Despite the clinic values that existing whole blood coagulation tests have demon-
strated, these systems have significant limitations that diminish their potential for
point-of-care applications. In this chapter, I leveraged recent advancements in small
scale device fabrication using functional soft materials [36] and developed a miniatur-
ized clot retraction assay device termed Miniaturized Hemoretractometer (mHRM).
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In the mHRM, two doubly-clamped mechanical strain sensing beams (in millimeter
size range) made with soft elastomer polydimethylsiloxane (PDMS) were utilized for
holding prescribed minute amounts of blood samples while simultaneously measuring
clot retraction force during blood clotting. Kinetic curves of clot retraction force
obtained by the mHRM were utilized for analysis of different major phases of clot
formation and extraction of key blood clotting parameters. Using mHRM, we further
conducted whole blood coagulation assays to determine the effect of assay temper-
ature, treatments of clotting agent, and pro- and anti-coagulant on clot retraction
force development.
2.2 Experimental section
2.2.1 Device design and fabrication
The mHRM device consisted of three sandwiched layers, with the middle struc-
tural layer containing two parallel doubly-clamped beams as mechanical strain sensors
to measure dynamic clot retraction force during blood clotting (Figure 2.1). In the
mHRM, the structural layer was embedded between a top cover layer and a bottom
support layer. Each strain sensing beam contained a protrusion in the middle of the
beam to hold a prescribed minute blood sample. In this proof-of-concept device, posi-
tions of fiducial markers engraved onto the protrusions of the strain sensing beam were
recorded using a camera during blood clotting assays for quantitative measurements
of beam displacements.
All the three layers of the mHRM device were fabricated through replica molding
of soft materials (Figure 2.2). Patterns of molds were first generated using AutoCAD
(Autodesk, Inc.). A laser cutter was used to cut acrylic sheet (Inventables, Inc.) into
desired patterns. These acrylic patterns were affixed to the bottom of a petri dish
using double-sided tape before degassed polydimethylsiloxane (PDMS) prepolymer
11
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Figure 2.1:
(a) Schematic of the mHRM. A structural layer containing two doubly-
clamped force sensing beams was sandwiched between a top cover layer
and a bottom support layer. Each force sensing beam contained a protru-
sion in the middle of the beam to hold whole blood samples. Positions of
fiducial markers engraved onto the protrusions were recorded for quanti-
tative measurements of beam displacements during blood clot formation.
(b) Photograph of the mHRM device.
(10:1 base-to-curing agent ratio) was poured into the petri dish. The dish was placed
in a 60 ◦C oven overnight, before PDMS was peeled off and cut into desired dimensions
to form the top cover and bottom support layers of the mHRM device.
The structure layer of the mHRM device containing doubly-clamped strain sensing
beams was fabricated using a double molding protocol. Briefly, an acrylic pattern was
first cut by laser into the same shape as the final structural layer before being used as a
mold to generate a negative mold using PDMS (10:1 base-to-curing agent ratio). Fidu-
cial markers were generated by engraving the acrylic sheet before the sheet was used
as a mold. After being cured and peeled off from the acrylic mold, the negative PDMS
mold was activated with oxygen/air plasma (PDC-001, Harrick Plasma), followed by
surface passivation with trichloro(1H,1H, 2H,2H-perfluorooctyl)silane (Sigma-Aldrich
Co.), before degassed PDMS prepolymer (20:1 base-to-curing-agent ratio) was poured
onto the mold and excess PDMS was removed using a razor blade. The negative
PDMS mold was then placed in a 60 ◦C oven for 6 hr before the final structural layer
was peeled off from the mold. The structural layer was briefly treated with air plasma
12
+Plasma bond
Pour in 
PDMS
Support 
layer
Structure 
layer
Dish
Acrylic 
mold
Liquid 
PDMS
Cure and 
peel off
Negative mold (PDMS)
Cure and 
peel off
Cure and 
peel off
Figure 2.2:
Fabrication of the mHRM device. The structure layer was fabricated by
a double molding protocol. Laser-cut acrylic mold was affixed onto a dish
before liquid PDMS prepolymer was poured in, which was then cured
and peeled off to form the negative mold. Liquid PDMS prepolymer was
then poured on the negative mold, with the excess PDMS being removed
using a blade. After curing, the final structure layer was peeled off from
the negative mold. Support layer was fabricated by single molding in a
similar way. The structure and support layer were bonded together after
surface activation with oxygen plasma.
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Figure 2.3:
Tensile testing methods. (a,b) Testing specimen and dimensions. (Unit:
mm) (c) Plotted stress-strain curve from the testing and the linear fit of
strain-stress relation. The Young’s modulus in this case was calculated
to be 313.3 kPa.
before being bonded with the bottom support layer (Figure 2.1b).
The fabrication protocol was established to generate mHRM devices with consis-
tent geometries (with standard deviations less than 4% of the mean; data not shown).
The width, length, and thickness of the doubly-clamped PDMS strain sensing beams
used in this work were 1.0 mm, 35.5 mm, and 2.0 mm, respectively. The millimeter
size scale of the mHRM facilitates its assembly process. Success rate of mHRM fabri-
cation was about 80%, with the cost of a single mHRM device estimated to be about
7 U.S. Dollars. We further used an Instron tensile testing machine (Norwood, MA)
to calibrate the Young’s modulus of PDMS prepared for the structural layer of the
mHRM device (Young’s modulus, ∼300 kPa; Figure 2.3).
2.2.2 FEM simulation
FEM simulation was performed in COMSOL Multiphysics (COMSOL, Inc.). Briefly,
a stationary solid mechanics model was developed with a beam subjected to gravity
(g = 9.8 m/s2). A downward vertical force was uniformly exerted on the protrusion
surface to mimic the effect of blood weight (70 µN). The Young’s modulus, density,
and Poisson’s ratio of PDMS were 300 kPa, 970 kg/m3, and 0.49, respectively. To
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Figure 2.4:
(a) FEM simulation of beam displacement showing stress distribution
and beam deformation when a prescribed horizontal load of 200 µN was
applied uniformly on the beam protrusion. (b) Beam displacement as
a function of horizontal load. Linear fitting was used to determine the
spring constant K of the force sensing beam.
simulate the effect of blood clotting and contraction on beam deformation, another
horizontal load was applied uniformly on the protrusion (Figure 2.4a). Through FEM
simulation, horizontal beam displacement was calculated as a function of horizontal
load, linear fitting of which provided the effective spring constant K of the PDMS
strain sensing beam (K = 0.206 µN/µm; Figure 2.4b), which would be used directly
for calculation of clot retraction force in experiments by multiplying K with horizon-
tal beam displacement. The spring constant K of the PDMS strain sensing beam was
further validated using the classical beam theory following
K = 16EδW 3/L3 (2.1)
where E was the Young’s modulus, and δ, W , and L were the beam thickness, width,
and length, respectively. K was calculated to be 0.206 µN/µm.
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2.2.3 Blood specimen and coagulation assays
Under a protocol approved by the University of Michigan’s Committee on Care
of Use of Animals, whole blood specimens were collected from healthy pigs into a
vacutainer (BD Vacutainer, BD Company) containing 3.2% sodium citrate. All blood
samples were assayed within 6 hr after blood collection.
Unless otherwise stated, all clot retraction force measurements were conducted
using re-calcified whole blood without additional pre-treatment. Briefly, 12.75 µL
citrated whole blood was suspended between the two protrusions of the PDMS strain
sensing beams by pipetting, before another 0.75 µL CaCl2 solution (0.2 M, Fisher
Scientific) was added into the blood drop. For mixing, a pipette was inserted into the
blood and stirred up gently. The top cover layer was then placed on top of the mHRM
device, and image acquisition was started immediately using a microscope coupled
with a digital camera (Dino-Lite Handheld Digital Microscope, AnMo Electronics
Co.) at one or two frames per minute. To minimize blood evaporation, water drops
were placed inside the mHRM device, and the surrounding area of the top cover layer
was applied with PDMS prepolymer before being placed on the structural layer of the
mHRM device. Coagulation assays at 37 ◦C were conducted in a stage-top incubation
chamber (PM S1, Zeiss, Inc.). Assays at 25 ◦C were performed in a room equipped
with a thermostat and air conditioning system.
To activate platelets and thus expedite clot retraction force development, 1 µL
thrombin (100 U/mL, Cayman Chemical Company) was added into the blood as a
clotting factor. To assay the effects of pro- and anti-coagulants on clot retraction
force development, aprotinin (80 µg/mL; Sigma-Aldrich Co.) and heparin (8 U/mL;
Sigma-Aldrich Co.) were further added into the blood in separate experiments. Drug
treated blood samples were incubated at room temperature for one hour before loaded
into the mHRM device for clot retraction force measurements.
Thromboelastography (TEG) was conducted using the TEG 5000 Thrombelas-
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tograph Hemostasis Analyzer System (Haemonetics Corp., Braintree, MA) following
standard protocols for citrated whole blood samples.
2.2.4 Image processing and data analysis
Images were processed via template matching using MATLAB (MathWorks, Inc.)
to obtain displacement data of doubly-clamped PDMS strain sensing beams. Briefly,
an area in the first image of the beam containing the fiducial markers was selected as
the template, and each of the following images was analyzed to determine the best
match of this template, the location of which was extracted for beam displacement
analysis. Displacements of doubly-clamped strain sensing beams were then converted
to clot retraction forces CRF using Hooke’s law.
The data of clot retraction force during the contraction development phase was
fitted using a quadratic function to obtain key coagulation parameters, including
reaction time Tr, time to maximum amplitude Tmax, CRF growth rate GCRF , and
maximum CRF CRFmax. Specifically, Tr was defined as the time when CRF started
to increase from the baseline level (CRF = 0 µN), time to maximum amplitude Tmax
was the time it took for CRF to reach its maximum value CRFmax, and GCRF was
defined as the CRF growth rate at Tr (GCRF = dCRF/dT |T=Tr). Statistical analysis
was conducted using Origin (OriginLab Corp.). Two-sample unpaired Student’s t-
test was performed, and only p-values less than 0.05 were considered statistically
significant.
2.3 Results
2.3.1 mHRM device design and characterization
Design of the mHRM device incorporated two doubly-clamped PDMS beams with
protrusions at the beam centers to hold blood samples (Figure 2.1). The doubly-
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clamped PDMS beams served simultaneously as mechanical strain sensors to report
clot retraction forces in real time during blood clotting, through direct measurements
of positions of fiducial markers engraved onto the protrusions of PDMS strain sensing
beams. A fabrication protocol was established to generate the mHRM device using
replica molding of PDMS (see Experimental section; Figure 2.2), resulting in consis-
tent and precise geometries of PDMS strain sensing beams and their distance, critical
for precise measurements of clot retraction force. The width, length, and thickness of
doubly-clamped PDMS strain sensing beams used in this work were 1.0 mm, 35.5 mm,
and 2.0 mm, respectively. The Young’s modulus of PDMS was further calibrated using
a standard tensile testing protocol to be about 300 kPa (see Experimental section),
consistent with previously published data [37]. We further conducted FEM simu-
lations to determine the effective spring constant K of the doubly-clamped PDMS
strain sensing beams (K = 0.206 µN/µm), which was then used directly for quan-
tification of clot retraction force by multiplying K with beam displacement (Hooke’s
law; Figure 2.4). During blood coagulation assays, 12.75 µL citrated whole blood was
suspended between the two protrusions of PDMS strain sensing beams by pipetting,
before another 0.75 µL CaCl2 solution (0.2 M) was added into the blood for re- calci-
fication and initiation of blood clotting. In order to understand if PDMS surface has
any intrinsic effect on blood coagulation, studies were undertaken in which we coated
TEG cups (blood receptacles) with PDMS. Blood was then added and TEG measure-
ments were performed. Results indicated that when compared to non-PDMS-coated
controls, PDMS had no measureable effect on blood coagulation (Figure 2.5).
Figure 2.6 demonstrates a temporal series of representative bright field images
showing clotting of a blood drop suspended between the two protrusions of PDMS
strain sensing beams recorded using a digital camera immediately after blood re-
calcification (designated as T = 0).
This blood coagulation assay was conducted at 25 ◦C, with 1 µL thrombin (100
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Figure 2.5:
Effect of PDMS on blood coagulation. (a) Comparison of TEG tracings
using regular TEG cups and cups pre-coated with PDMS. (b) Bar plots of
reaction time Tr, time to maximum amplitude Tmax, and maximum TEG
amplitude as a function of PDMS coating. Data represents the mean ±
SEM with n = 5. P -values were calculated using two-sample unpaired
student t- test.
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Figure 2.6:
(a) Representative micrographs showing the dynamic process of blood clot
formation at different time points. Blood clotting and contraction caused
the two opposite force sensing beams to bend toward each other. Posi-
tions of fiducial markers were determined through image processing for
quantitative measurements of beam displacements and thus clot retrac-
tion force CRF . Scale bar, 1 mm. (b) Beam displacement as a function
of time, with t = 0 being the moment of thrombin and calcium addition
(see Experimental section), for three different mHRM devices. Data rep-
resents the mean ± SEM. (c) Clot retraction force CRF calculated based
on the spring constant K of the doubly-clamped force sensing beam and
beam displacement.
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U/mL) added into the blood prior to mHRM measurement. Thrombin, as a common
clotting factor, is an important intermediate product of the blood coagulation process
and cleaves fibrinogen to form fibrin networks. Thus, adding thrombin into blood can
expedite the coagulation cascade in a positive feedback fashion. Importantly, throm-
bin also directly activates platelets and induces platelet contraction [38]. Imaging
analysis was conducted to quantify displacement of fiducial markers (and thus strain
sensing beams) as a function of time to determine dynamic clot retraction force CRF
during blood clotting (Figure 2.6b & c). Data of PDMS strain sensing beam dis-
placement and clot retraction force shown in Figure 2.6b & c were obtained from
three separate coagulation assays using three different mHRM devices, suggesting
consistent measurements and satisfactory reproducibility of the mHRM device for
clot retraction force measurements (SEMs were generally around 6% of the mean
CRF ).
2.3.2 Dynamic clot retraction force development
Kinetic curves of clot retraction force obtained by the mHRM device helped reveal
different major phases of clot formation (Figure 2.7), consistent with those revealed by
TEG (Figure 2.8). In the first reaction phase between blood re-calcification (T = 0)
and onset of clot retraction force development (T = Tr), clot retraction force was
essentially zero and not detected by the mHRM (Figure 2.6b & c). In this reac-
tion phase, the coagulation cascade was underway for formation of the fibrin network
needed for clot retraction force development. Onset of clot retraction force develop-
ment occurred as soon as the fibrin network was in place, and interactions between
activated platelets and fibrin strands led to a rapid increase of clot retraction force
and initiation of blood clot contraction (“the contraction development phase”; Fig-
ure 2.7). In the contraction development phase, clot retraction force CRF increased
rapidly before approaching a plateau (CRFmax; Figure 2.7). We designated duration
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Figure 2.7:
Schematic of dynamic evolution of the CRF during the whole blood co-
agulation process. Key parameters, including reaction time Tr, time to
maximum amplitude Tmax, CRF growth rate GCRF , and maximum CRF
CRFmax, were highlighted.
of the reaction phase as Tr and the time it took for clot retraction force to reach its
maximum as Tmax. Growth rate of clot retraction force GCRF was defined as
GCRF =
dCRF
dT
∣∣∣∣
T=Tr
(2.2)
Kinetic curves of clot retraction force measured by the mHRM further revealed a
clot lysis phase immediately following the contraction development phase, similar to
those observed in TEG. In the fibrinolysis phase, clot retraction force decreased slowly
from the plateau value CRFmax due to fibrin network being disintegrated. Together,
the reaction time Tr, time to maximum clot retraction force Tmax, clot retraction
force growth rate GCRF , and maximum clot retraction force CRFmax measured by
the mHRM provided a set of parameters for us to assess the full complexity of the
coagulation system and for global measurement of the hemostasis under different
clotting agent and pro- and anti-coagulant treatments.
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Figure 2.8:
Schematic of the TEG tracing plotted with both the dynamic amplitude
curve and its mirror as the TEG instrument readout, with key parameters
highlighted. TEG tracing showed similar dynamic pattern as that in
mHRM, with R correspondent to reaction time Tr, TMA correspondent
to time to maximum amplitude Tmax, α correspondent to CRF growth
rate GCRF , and MA correspondent to maximum CRF CRFmax in mHRM
tracing.
2.3.3 Effect of temperature on clot retraction force
Low body temperature (hypothermia) is known to slow down blood clotting pro-
cess [39]. To illustrate the utility of the mHRM for blood coagulation tests, we first
examined the effect of temperature on clot retraction force development using the
mHRM. Blood coagulation was initiated by re-calcification but without supplemen-
tation of the clotting factor thrombin. Compared to that at room temperature (25
◦C), development of clot retraction force during blood coagulation was significantly
expedited at 37 ◦C, with significantly shortened reaction time Tr and time to max-
imum amplitude Tmax (Figure 2.9). Growth rate of clot retraction force GCRF was
significantly increased at 37 ◦C as compared to 25 ◦C (Figure 2.9a). Specifically, the
reaction time Tr, time to maximum amplitude Tmax, and growth rate of clot retraction
force GCRF were 8.70 ± 0.62 min, 22.8 ± 1.59 min, and 3.50 ± 0.59 µN/min, respec-
tively, at 37 ◦C (Figure 2.9b). While at 25 ◦C, Tr, Tmax, and GCRF were 24.63± 3.10
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Figure 2.9:
Effect of temperature on clot retraction force. (a) Clot retraction force
CRF measured by mHRM plotted as a function of time, at both 37 ◦C and
25 ◦C. (b) Bar plots of reaction time Tr, time to maximum amplitude
Tmax, CRF growth rate GCRF , and the maximum CRF CRFmax as a
function of temperature. Data represents mean ± SEM with n = 4 at 25
◦C and n = 5 at 37 ◦C. **, P < 0.01. N.S., P > 0.05.
min, 80.25 ± 4.96 min, and 0.80 ± 0.15 µN/min, respectively (Figure 2.9b). Even
though the dynamic properties of clot retraction force development appeared sensi-
tive to temperature, the maximum clot retraction force CRFmax was not significantly
different between 37 ◦C and 25 ◦C, with CRFmax = 27.21 ± 5.53 µN at 37 ◦C and
CRFmax = 25.19 ± 3.01 µN at 25 ◦C (Figure 2.9b). These temperature-dependent
dynamic behaviors were likely the direct effect of different enzyme activity at different
temperatures. At 37 ◦C, coagulation-related enzymes, such as the clotting factors,
were more active and thus the coagulation cascade progressed rapidly. In contrast, at
25 ◦C, these enzymes were less active, so the reaction phase became longer and the
CRF also took longer to develop.
2.3.4 Effect of thrombin on clot retraction force
We conducted blood coagulation assays using the mHRM at 25 ◦C to specifically
examine the effect of the clotting factor thrombin on clot retraction force develop-
ment. After blood re-calcification, 1 µL thrombin (100 U/mL) was added into the
blood prior to mHRM measurement. Indeed, compared to re-calcified blood without
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Figure 2.10:
Effect of thrombin activation on clot retraction force. All experiments
were conducted at 25 ◦C. (a) Clot retraction force CRF measured by
mHRM plotted as a function of time, for blood samples with or without
thrombin treatment, as indicated. (b) Bar plots of reaction time Tr,
CRF growth rate GCRF , and CRF at 60 min (CRF60) as a function of
thrombin activation. Data represents mean ± SEM with n = 6 (with
thrombin) and n = 4 (without thrombin). **, P < 0.01.
thrombin treatment, thrombin activation resulted in significantly shortened reaction
time Tr before the onset of clot retraction force development and greater growth rate
of clot retraction force GCRF (Figure 2.10). Specifically, with thrombin treatment,
the reaction time Tr and growth rate of clot retraction force GCRF were 7.50 ± 0.34
min and 1.60 ± 0.08 µN/min, respectively, whereas without thrombin activation, Tr
and GCRF were 24.63 ± 3.10 mm and 0.80 ± 0.15 µN/min, respectively. One hour
after blood re-calcification (T = 60 min), the clot retraction force reached a level of
37.12± 2.77 µN under thrombin treatment (CRF60 = 37.12± 2.77 µN), much greater
compared to untreated control (CRF60 = 25.19± 3.01 µN).
2.3.5 Effects of pro- and anti-coagulants on clot retraction force
To demonstrate the effectiveness of the mHRM for rapid assessment of the effects
of pro-coagulant and anti-coagulant medications on the global hemostasis response,
we conducted comparative studies using the mHRM at 25 ◦C on blood samples treated
with either aprotinin (pro-coagulant; 80 µg/mL) or heparin (anti-coagulant; 8 U/mL).
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Blood samples were re-calcified and supplemented with thrombin after treatments
with aprotinin or heparin. Aprotinin is a broad-spectrum serine protease inhibitor
with significant abilities to inhibit fibrinolysis. It has been used in coronary artery
bypass grafting surgery to reduce blood loss and transfusion requirement [40, 41].
As a well-studied anticoagulant, heparin can bind and potentiate antithrombin III, a
major inhibitor of thrombin. Thus, treatment of heparin can effectively inhibit blood
coagulation [42]. As expected, heparin treatment indeed suppressed blood clotting
completely (Figure 2.11a). No clot retraction force was detected by the mHRM during
the entire one hour assay period. In fact, blood samples treated by heparin were still
in a liquid phase with no gelation observed at the end of the assay. We should also
note that heparin-treated blood samples, with their clotting completely suppressed,
served as negative control demonstrating that the intrinsic viscoelastic property of
blood had minimal effect on inducing displacements of force-sensing beams in the
mHRM (Figure 2.11a).
Aprotinin treated blood, in distinct contrast, demonstrated rapid blood clotting
and strong clot retraction. The reaction time Tr and growth rate of clot retraction
force GCRF for aprotinin treated blood were comparable to blood samples treated
with thrombin alone (for aprotinin treated blood, Tr = 5.00± 2.08 min, and GCRF =
1.71± 0.10 µN/min; for thrombin treated control, Tr = 7.50± 0.34 min, and GCRF =
1.60 ± 0.08 µN/min). However, clot retraction force at T = 60 min (CRF60) was
significantly greater for aprotinin treated blood compared to thrombin treated control
(CRF60 = 51.38±2.70 µN for aprotinin treated blood, and CRF60 = 37.12±2.77 µN
for thrombin treated control, Figure 2.11b). This observation was consistent with the
functional role of aprotinin in inhibiting fibrinolysis and preserving platelet contractile
function during blood clotting.
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Figure 2.11:
Effect of pro- and anti-coagulants on clot retraction force. All experi-
ments were conducted at 25 ◦C with blood re-calcified and supplemented
with thrombin. (a) Clot retraction force CRF measured by mHRM
plotted as a function of time, for blood samples pre-treated with apro-
tinin (pro-coagulant) and heparin (anti-coagulant). Control without any
pro- or anti- coagulant treatment was included for comparison. (b) Bar
plots of reaction time Tr, CRF growth rate GCRF , and CRF at 60 min
(CRF60). Data represents mean ± SEM with n = 3 (aprotinin treated),
n = 6 (control), and n = 6 (heparin treated). **, P < 0.01. N.S.,
P > 0.05.
2.3.6 Comparison of mHRM with TEG
Coagulation diagnostics using whole blood samples is currently conducted with
technologies such as TEG, ROTEM, and HAS. These whole blood coagulation mon-
itoring methods have provided critical information on the major phases of clot for-
mation and lysis. The HAS system is no longer produced. To compare the kinetic
signatures of clot retraction force development measured by mHRM with those ob-
tained from TEG, we conducted additional coagulation assays with re- calcified whole
blood at both 37 ◦C and 25 ◦C using TEG. At 37 ◦C, clot retraction force measured by
mHRM showed very similar dynamics with data obtained from TEG (Figure 2.12a).
The reaction time Tr and time to maximum amplitude Tmax obtained from mHRM
were 8.70± 0.62 min and 22.8± 1.59 min, respectively, comparable with values from
TEG, where Tr = 7.68 ± 1.07 min and Tmax = 24.28 ± 2.46 min (Figure 2.12b).
However, at 25 ◦C, clot retraction force development in the mHRM was significantly
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slower than blood clotting in TEG (Figure 2.12c & d). Specifically, reaction time
Tr and time to maximum amplitude Tmax in the mHRM were 24.63 ± 3.10 min and
80.25 ± 4.96 min, respectively, while in TEG, Tr and Tmax were only 9.22 ± 1.92
min and 32.92 ± 2.07 min, respectively. Slower clot retraction force development in
the mHRM at 25 ◦C when compared to TEG might be attributed to the shear ap-
plied to clotting blood in the TEG. It has been well reported in the literature that
fluid shear can increase platelet adhesion, aggregation, and thus activation. Applying
quasi-static Couette flow model to TEG experimental setup, the shear rate in TEG
was estimated to be about 0.2 s-1, which might be sufficient for eliciting platelet ac-
tivation [43–45]. A higher temperature at 37 ◦C might lead to expedited biochemical
reactions in the coagulation cascade, masking the effect of shear stress on promoting
blood coagulation.
2.3.7 Future development for point-of-care testing
Blood coagulation assays for point-of-care applications will require such assays
to be fast, robust, yet easy to operate. In its current form, measurements of clot
retraction force by the mHRM take about tens of minutes, which is still suboptimal
for point-of-care applications. A potential solution to expedite blood coagulation in
the mHRM will be to supplement coagulation activators, such as kaolin, into blood
samples, as has been commonly conducted in TEG. Specifically, kaolin can signifi-
cantly shorten the reaction time Tr and increase the clot retraction force growth rate
GCRF during blood clotting [46].
Currently, the mHRM requires optical microscopy for image collection. Future
effort will be devoted to develop a small diagnostic accessory - a “dongle” - that
attaches to a smartphone and has the capability for automatic blood sample loading
and precise temperature control. Blood coagulation assays can be run automatically
by the dongle on a disposable plastic cassette with preloaded reagents, with results
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Figure 2.12:
Comparison of mHRM and TEG for blood clotting tests at both 37 ◦C
(a & b) and 25 ◦C (c & d). (a & c) Clot retraction force CRF measured
by mHRM and TEG rotational amplitude plotted as a function of assay
time, at both 37 ◦C (a) and 25 ◦C (c). (b & d) Comparison of reaction
time Tr (left) and time to maximum amplitude Tmax (right) measured
by mHRM and TEG at both 37 ◦C (b) and 25 ◦C (d), as indicated. Data
represents the mean ± SEM with n = 5. **, P < 0.01. N.S., P > 0.05.
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captured by smartphone camera and processed simultaneously by the smartphone.
We envision that coupling the mHRM technology with recent advances in consumer
electronics will lead to the convenience of obtaining quick whole blood coagulation
diagnostics results with a single fingerprick, making the existing laboratory-based
coagulation diagnostics accessible at home and to almost any population with access
to smartphones.
Precise metering of blood sample is critical for accurate measurements of blood
coagulation properties. In point-of-care testing using the mHRM, we envision blood
sampling to be performed through finger prick in conjunction with a capillary tube
that is coupled with a syringe-like dispenser. When blood has been collected in the
capillary tube, the dispenser will be connected to the capillary tube and discharge a
precise amount of blood onto force sensing elements of the mHRM. Due to hydropho-
bicity of PDMS and surface tension, blood drops with a prescribed volume will acquire
the same shape and position as long as they are properly suspended between force
sensing beams in the mHRM.
2.4 Conclusion
The coagulation system is a complex biological system, which balances coagula-
tion and fibrinolysis in an effort to maintain both blood flow and hemostasis. In
addition to the acellular (clotting proteins) and cellular (red blood cells, platelets,
white blood cells) components of the coagulation system, it is now appreciated that
coagulation is also affected by inflammation, tissue oxygenation, and endothelial cell
function. There is a growing trend in using technologies to examine blood coagulation
to monitor standard coagulation therapies in both thrombolic and hemophilic diseases
as well as for diagnostic and therapeutic purposes to guide transfusion therapy and
treatments for sepsis, traumatic brain injury, and other acute diseases. Coagulation
monitoring technologies using whole blood samples such as TEG and ROTEM are
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now becoming increasingly common because unlike traditional PT and aPTT tests,
which examine only the protein portion of the blood, TEG and ROTEM examine
both cellular and acellular components involved in blood coagulation and can thus
provide a more complete picture of the interactions between the coagulation and in-
flammatory systems. However, despite the important clinical values that TEG-like
technologies can bring, existing whole blood coagulation assays share some critical
limitations (such as high cost, limited sample throughput, large footprint, etc.) that
have rendered them suboptimal for point-of-care applications. In this chapter, I have
successfully developed a miniaturized clot retraction assay device termed Miniaturized
Hemoretractometer (mHRM) using soft elastic material PDMS and replica molding.
Doubly-clamped flexible PDMS beams were incorporated into the mHRM design to
serve as mechanical strain sensors to report clot retraction force development dur-
ing blood clotting. Importantly, kinetic curves of clot retraction force obtained by
the mHRM have demonstrated different major phases of clot formation (including
the reaction phase, contraction development phase, and fibrinolysis phase), consis-
tent with TEG/ROTEM. Key blood clotting parameters including reaction time Tr,
time to maximum clot retraction force Tmax, clot retraction force growth rate GCRF ,
and maximum clot retraction force CRFmax can be conveniently determined by the
mHRM, allowing full assessment of the complexity of the coagulation system and
for global measurement of the hemostasis. To demonstrate its clinical utility, the
mHRM was utilized for clot retraction force measurements of whole blood samples
under different assay temperature, different clotting agent (i.e., thrombin), and pro-
(i.e., aprotinin) and anti-coagulant (i.e., heparin) treatments. This preliminary effort
demonstrated the ability of the mHRM to detect changes in coagulation consistent
with those expected when blood was exposed to various pro- and anti-coagulant
medications. This lays the foundation to identify novel signatures of blood clotting
dynamics under perturbations to different coagulation components, which will allow
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tailoring of specific coagulation tests and treatments to different clinical applications
in the future. The mHRM’s low fabrication cost, small size, and consumption of only
minute amounts of blood samples make the technology promising as a point-of-care
tool for coagulation monitoring.
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CHAPTER III
Capillary assisted deposition of carbon nanotube
film for strain sensing
This chapter is in part adapted from:
Li, Zida, Xufeng Xue, Feng Lin, Yize Wang, Kevin Ward, and Jianping Fu.
“Capillary assisted deposition of carbon nanotube film for strain sensing.”
Applied Physics Letters 111, no. 17 (2017): 173105.
3.1 Introduction
In the current form of mHRM, data acquisition replies on optical instruments,
including back light and camera; it makes data collection cumbersome and hinders
mHRM’s applications for point-of-care testing. To miniaturize the data acquisition
setup of mHRM, a potential method is to incorporate electrical components that are
strain-sensitive into the force-sensing beams. Such devices would significantly simply
the data acquisition setup and also allow real-time CRF monitoring.
Conventional electronics, which is based on printed circuit boards and silicon
wafers, is inherently rigid and lacks flexibility and stretchability. While the main-
stream research in conventional electronics has been focused on developing faster and
smaller units on planar surfaces, there is an emerging development of stretchable
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devices for applications such as wearable electronic devices and health monitoring
sensors. The curvy nature of biological objects requires electronics to be stretchable
to ensure conformable contact. Such need of stretchability led to the emerging field
of stretchable electronics [47].
Two major concepts have been successfully adopted for developments of stretch-
able electronics. One is to make specially designed thin structures before transferring
them onto stretchable substrates such as polymers, forming either wavy or island-
bridge structures [48]. Such design minimizes strain in the brittle silicon or metal
materials and allows bending and stretching. Successful applications in skin sen-
sor [49], cardiac monitoring [50], etc., have been reported using this approach. The
other concept applies new functional materials, oftentimes combined with polymers,
to make elastic conductors. Among these new materials, carbon nanotube (CNT) is
one of the most commonly used given its exceptional electronic properties. Besides
its diverse semiconducting properties as a result of tunable chirality [51], CNT has
great electron mobility and thus excellent conductivity. In addition, though single
CNT has high Young’s modulus, carbon nanotube network shows good stretchability
[52].
Direct growth based on chemical vapor deposition (CVD) has been the most com-
mon fabrication method of CNT films [53]. Such methods fabricate CNT films with
good conductivity; however, they generally require high temperature, which is not
compatible with most polymer substrates. Alternatively, solution-based deposition
methods are more friendly to polymer substrates, although the conductivity of CNT
films is compromised compared to CVD [53].
Many methods based on solution deposition have been proposed, including dip
coating[54], contact printing [55], inkjet printing [56], solution precipitation [57], and
spray coating [58]. However, these methods are either complicated to implement or
not capable of generating desired patterns on substrates. In this chapter, we report
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a simple yet convenient method to generate patterns of piezoresistive CNT films
on the surfaces of elastic polydimethylsiloxane (PDMS). In particular, micropillar
arrays were fabricated on the PDMS surfaces before these surfaces were rendered
hydrophilic. After CNT solutions were dispensed onto the PDMS surfaces, capillary
action drove the solution evenly onto the surface areas covered with micropillars.
Water evaporation left a uniform film of CNT deposited on the PDMS surface, with
the shape of the envelope of the micropillar array. The effects of CNT concentration
and micropillar gap size on coating uniformity, conductivity, and piezoresistivity of
CNT films were studied. Our capillary assisted deposition method of CNT film show
the potential of being applied in fabrication of flexible CNT thin films for strain
sensing [59], which can be used in motion sensors in stretchable electronics as well as
in contraction sensors in biomedical devices.
3.2 Experimental section
3.2.1 Preparation of CNT solution
Carboxyl-functionalized multi-walled carbon nanotubes (Cheap Tubes Inc.) were
dispersed in deionized water at a concentration of 5 mg/mL using a probe sonicator
(Model VCX130, Sonics & Materials Inc.). Dispersed CNT solutions were then cen-
trifuged at 1000 g for 10 min with resultant supernatants extracted as stock CNT
solution for later use. The final CNT concentration in the stock CNT solution was
1.616±0.083 mg/mL, as measured by weighing precipitated CNT after complete wa-
ter evaporation. The CNT stock solution was diluted to generate CNT solutions of
lower concentrations.
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3.2.2 Fabrication of micropillar array and CNT film
Square-shaped micropillars were designed with the gap distance between adjacent
pillars same as micropillar side, to keep the pillar coverage constant on PDMS surfaces.
Unless otherwise noted, both the side of and gap size between micropillars were 100
µm. Micropillar arrays were fabricated using soft lithography. Briefly, a silicon wafer
with a negative pattern of the micropillar array was fabricated by photolithography
followed by deep reactive ion etching. The pillar height was 51.13 ± 0.55 µm, as
measured with a stylus profiler (DektakXT, Bruker Corporation). The silicon wafer
was then silanized for 4 hr before spin coating PDMS prepolymer (20:1 base-to-curing
agent ratio). Spin coating was performed at 600 rpm for 60 s, resulting in PDMS films
with a thickness of 105.0 ± 1.0 µm. The PDMS-coated wafer was then baked at 60
◦C overnight before the PDMS film was peeled off. The PDMS film was then treated
with oxygen plasma (Model PDC-001, Harrick Plasma) for 3 min to turn the PDMS
surface hydrophilic. CNT solution was then dispensed at a corner of the micropillar
array, typically at a volume of 2 µL, which then spread over the micropillar array
evenly. The PDMS film was then placed in a vacuum chamber to accelerate water
evaporation and minimize CNT aggregation.
The micropillar array was designed with a dog-bone-shaped envelope to assist
electrical measurements. Electrical resistance was measured with a digital multime-
ter (Model 34401A, Agilent Technologies), with conductive grease (Model 846, MG
Chemicals) applied to both ends of the dog-bone shape to minimize contact resis-
tance. For measurements of electromechanical properties of CNT films, the PDMS
film with micropillars was laid on a soft PDMS block (30:1 base-to-curing agent ratio)
before the CNT film was deposited. The PDMS block was then laid across a station-
ary stage and a translation stage mounted on an optical table. Gradual movement of
the translation stage led to straining of the PDMS film, with position marks on the
translation stage recorded for strain calculation.
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Phase contrast images were recorded with an inverted microscope (Zeiss Axio
Observer Z1, Carl Zeiss AG), and scanning electron images were taken with a cold
field emission scanning electron microscope (SU8000 In-line FE-SEM, Hitachi High-
Technologies). Raw CNT samples were prepared by dispersing CNTs in water with
vortex, instead of sonication to avoid damaging CNT structures [60], before dispensing
the CNT solution on a flat PDMS surface. Other samples were imaged as they were.
3.2.3 Data analysis
To construct grayscale histograms, pixels within the deposited areas in the pho-
tographs were extracts in Python, and the grayscale distributions were analyzed.
CNT film coverage on PDMS surfaces was analyzed by image processing. Phase con-
trast images of CNT films were recorded, and regions within channels were cropped for
processing in Adobe Photoshop (Adobe Systems Incorporated). Specifically, cropped
images were converted into binary images, turning regions covered by CNT black and
otherwise white. Total areas of these two regions were calculated in ImageJ (NIH,
USA). Data fitting was performed in Origin (OriginLab Corp.) or Python.
3.3 Results
3.3.1 Micropillar array suppressed coffee ring effect
The PDMS micropillar array had two major effects on deposition of CNT films
on PDMS surfaces. First, when CNT solution was dispensed on PDMS surfaces,
capillary force facilitated CNT solution spreading and confined CNT solution in the
area with micropillars. Such confining effect provided an effective way to pattern
the CNT film. Second, the micropillar array restrained the coffee ring effect. Coffee
ring effect originates from the compensating flow that keeps the contact line fixed
[60], making particle deposition concentrated on the liquid perimeter, as shown in
36
PDMS
Without micropillars With micropillars
Solvent
evaporation
Figure 3.1:
Schematic showing capillary assisted deposition of CNT films on PDMS
surfaces.
1 mm
Without micropillars With micropillars
Figure 3.2:
Photograph showing CNT deposited on PDMS surfaces without (left) or
with (right) micropatterned structures.
Figure 3.1. The micropillar array provided multiple evenly distributed contact lines,
suppressing the coffee ring effect and thus leading to a more uniform CNT deposition
compared to PDMS surfaces without micropillar arrays (Figure 3.2 & 3.3).
The CNT film deposited on PDMS surfaces with micropillar arrays also showed
good uniformity at the microscale, as demonstrated by phase-contrast and scanning
electron microscope images (Figure 3.4). Compared to raw CNTs, CNTs were broken
up into smaller bundles in the stock solution by sonication during sample preparation
(see Experimental section). For example, at a concentration of 0.808 mg/mL, CNTs
appeared as individual fibers in contact with neighboring fibers, forming a connected
network. The thickness of deposited CNT films was about 40 nm, as measured by
the atomic force microscopy (Figure 3.5a).
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Figure 3.3:
Grayscale distributions of the circular areas deposited with CNT in Fig-
ure 1b, on PDMS surfaces without micropillars (a) and with micropillars
(b). Smaller standard deviation of these histograms suggests a narrower
grayscale distribution and thus a more uniform CNT deposition. The
standard deviation of grayscale histograms for CNT films deposited on
PDMS surfaces with micropillars (0.036) was about one fifth of that with-
out micropillars (0.156).
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Figure 3.4:
(a) Phase-contrast image showing CNT film (1.616 mg/mL) deposited on
a PDMS surface with a patterned regular array of squared shaped pillars.
(b-d) SEM images show unprocessed CNT materials and CNT films with
different concentrations deposited on PDMS surfaces as indicated.
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(a) (b)
2 mm
Figure 3.5:
(a) Atom force microscope image of the CNT film deposited at 0.808
mg/mL. (b) Photograph of the dog-bone shaped CNT film for resistance
measurement.
3.3.2 Conductance of CNT film in agreement with percolation theory
We investigated the conductivity of deposited CNT films and its dependence on
CNT concentration. With a CNT concentration of 1.616 mg/mL, the conductivity
of CNT film was 11.16 ± 1.23 µS · sq−1. As CNT concentration became lower, CNT
film conductivity decreased exponentially (Figure 3.6), consistent with the percola-
tion theory studying through pathways of randomly connected clusters in a random
graph [61, 62]. Specifically, our data agreed well with predictions made by the perco-
lation theory that simulates each CNT fiber as a conducting stick (CS), overlapping
with other CNTs and forming a connected network. The percolation theory predicts
that the conductivity of a two-dimensional film depends on the density of particles
following
σ ∝ (N −Nc)α (3.1)
where σ is conductivity, N is CS density, Nc is the critical CS density above which
percolation happens, and the exponent α = 1.33 [61]. The CS density scales linearly
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Figure 3.6:
Sheet resistance (top) and conductance (bottom) as a function of CNT
differential concentration as defined in Equation 3.2.
with CNT concentration, which gives
σ ∝ (ρ− ρc)α (3.2)
where ρ is CNT concentration and ρc is the critical CNT concentration. Fitting of
the CNT sheet conductance experimental data using Equation 3.2 gave ρ of 0.308
mg/mL and an exponent α of 1.61, which was close to the theoretical value of 1.33
but somewhat greater. This discrepancy potentially resulted from the fact that CNT
films deposited on PDMS surfaces were not perfectly two-dimensional, which was
particularly evident at higher CNT concentrations (Figure 3.4c). The percolation
theory predicts the critical exponent α of 1.94 for a three-dimensional, randomly
connected clusters [61].
3.3.3 Effect of micropillar gap size
Micropillar gap size is a major geometric parameter that affects CNT film deposi-
tion on PDMS surfaces, since it directly relates to the contact line number, affecting
the extent of coffee ring effect and thus CNT film deposition [60]. We thus sought to
determine the micropillar gap size that could result in optimal CNT film deposition.
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Here, we define CNT film surface coverage as the ratio of areas covered with CNT to
the total area of the channel bottom. As shown in Figure 3.7a & b, micropillar arrays
with a gap size of 80 µm and 150 µm had a high surface coverage of 79.3± 1.0% and
76.4±2.4% by CNT films, respectively. When the micropillar gap size became smaller
or larger out of this range, deposited CNT films became less uniform with less surface
areas covered by deposited CNT films. For example, for micropillar gap sizes of 40
µm and 200 µm, the CNT film coverage was 52.1±7.0% and 58.7±2.2%, respectively.
The biphasic effect of micropillar gap size on CNT film coverage was possibly due
to multifaceted effects of micropillars on CNT film deposition. The coffee ring effect
predicts that solute deposition tends to concentrate around the contact line. As a
micropillar array with a smaller gap size has closer contact lines, CNT deposition is
supposedly more uniform. However, due to capillary action, CNT solution tends to
climb up micropillars and form meniscus, which inevitably results in heightened CNT
deposition close to pillar side walls. Thus, the micropillar array with 40 µmgap size
had more contacts between CNT solution and pillar walls and thus more meniscus,
which potentially led to less uniform CNT deposition on PDMS surfaces.
Sheet conductance of CNT films showed a different dependence on micropillar gap
size compared to CNT film coverage (Figure 3.7c). When the micropillar gap size was
less than 80 µm, similar as CNT film coverage, the sheet conductance was reduced.
For example, the sheet conductance of CNT film with micropillars with 40 µm gaps
(5.80 ± 0.77 µS · sq−1) was about half of that of CNT film with micropillars with
80 µm gaps (10.76± 1.20 µS · sq−1). However, when the micropillar gap was greater
than 80 µm, unlike CNT film coverage, the CNT sheet conductance remained roughly
unchanged around 12 µS · sq−1. Specifically, when the micropillar gap size increased
from 80 µm to 200 µm, while the CNT film coverage reduced from 79.3 ± 1.0% to
58.7 ± 2.2%, the sheet conductance became 12.68 ± 1.38 µS · sq−1, not significantly
different from 10.76 ± 1.20 µS · sq−1 at 80 µm gap size (P > 0.05). This was likely
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Figure 3.7:
Effect of pillar gap size on coating uniformity and conductivity of CNT
film. (a) Micrographs of CNT films deposited on PDMS surfaces with
micropillar arrays with different gap sizes as indicated. (b & c) Coverage
(b) and sheet conductance (c) of CNT films deposited on PDMS surfaces
as a function of micropillar gap size.
because at 200 µm, even though CNTs showed more aggregation and the CNT film
coverage was reduced, CNT fibers were still connected (Figure 3.7a) and thus the CNT
sheet conductance was not significantly affected. In contrast, with 40 µm micropillar
gap size, CNT fibers formed discrete islands, rendering the whole CNT film less
conductive.
3.3.4 CNT films showed good piezoresistivity
To explore the potential use of deposited CNT films for strain sensing, we specifi-
cally measured electromechanical properties of CNT films deposited at different con-
centrations including their gauge factors. We fabricated CNT films in dog-bone shapes
(Figure 3.5b) and applied uniaxial stretch along the axial direction of the bone shape
while simultaneously monitoring electrical resistance changes of deposited CNT films.
As shown in Figure 3.8, when the CNT concentration was 0.808 mg/mL and 1.212
mg/mL, the gauge factor of deposited CNT films increased with applied strain, con-
sistent with previous reports [63]. For example, for CNT concentration of 1.212
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Figure 3.8:
Relative resistance change (a) and corresponding gauge factor (b) of CNT
films at different CNT concentrations as a function of strain.
mg/mL, the gauge factor of deposited CNT films was 34.7 and 213.6 with a strain
of 0.01 and 0.058, respectively (Figure 3.8 b). However, when CNT concentration
was increased to 1.616 mg/mL, the relative resistance change of deposited CNT films
appeared linearly increasing with applied strain (R2 = 0.99, data not shown; Fig-
ure 3.8a), leading to a relatively constant overall gauge factor of about 71.8 (Figure
3.8b). The linear dependence between relative resistance change and applied strain at
this CNT concentration showed the potential of the CNT films for straining sensing
applications.
3.4 Conclusion
Carbon nanotube, as an emerging smart functional nanomaterial, has unique elec-
trical properties, rendering them very promising for applications in stretchable elec-
tronics. In this work, we report a simple but convenient method for uniform deposi-
tion of thin CNT films as strain sensing functional materials on flat PDMS surfaces
by fabricating micropillar arrays on the PDMS surfaces and rendering the surfaces
hydrophilic through plasma treatments. Owing to capillary forces, CNT solutions
dispensed on PDMS surfaces would cover the surfaces uniformly with the shape of
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the micropillar array. Importantly, the micropillar array would suppress the coffee
ring effect to ensure uniform CNT coating on the PDMS surfaces after water evap-
oration. We studied different parameters that could affect the quality of CNT film
deposition, including CNT concentration and micropillar gap size.
Compared to other solution-based CNT deposition processes such as spray coating,
our method does not require stencil for patterning and thus it is more suitable in
applications where CNT patterning is desirable. Our method is also compatible with
most soft-lithography based fabrication processes, making it easily applicable to other
research laboratories. We believe this method will find applications in strain sensing
in stretchable electronics as well as contraction force measurements in biomedical
researches [64, 65].
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CHAPTER IV
The CNT-strain-sensor-based hemoretractometer
for blood clot retraction testing
This chapter is in part adapted from:
Li, Zida, Yize Wang, Xufeng Xue, Brendan McCracken, Kevin Ward, and
Jianping Fu. “Carbon Nanotube Strain Sensor Based Hemoretractome-
ter for Blood Coagulation Testing.” ACS Sensors, DOI: 10.1021/acssen-
sors.7b00971 (2018)
4.1 Introduction
This thesis aims to develop a micro-engineered device for blood clotting assay
with the potential of point-of-care applications. Such devices have many merits as
compared to conventional blood coagulation assay, such as small device size, low blood
consumption, low lost, and high throughput, which could greatly improve patient care
and decision making in clinical settings such as perioperative hemostatic monitoring
[66], transfusion therapies [67], thrombosis (atrial fibrillation, DVT, PE) treatments
[68], hemophilic disease treatments, and treatments for multisystem trauma, sepsis,
traumatic brain injury, and other acute diseases [26].
In Chapter 2, I discussed the design of an image-based hemoretractormeter and
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demonstrated its utility. The design successfully captured key signatures in coag-
ulation profiles and differentiated blood samples under different drug treatments.
Nonetheless, mHRM’s data acquisition relied on image capturing using a digital mi-
croscope [64]. Such microscopes required certain working distance and a sturdy stand
to minimize the vibration during image collection, which could be problematic in a
point-of-care testing scenario. To this end, incorporation of electrical units into the
PDMS force sensor is beneficial; electrical units generate electrical signal that can be
conveniently collected and analyzed by an integrated circuit chip, which significantly
reduces the size of the instrumentation. Additionally, replacing digital microscope
with IC chips reduces the cost.
Motivated by this concept, in Chapter 3, I developed a method to conveniently
coat CNT on PDMS and characterized the piezoresistivity of the resultant CNT films.
Results showed that the deposited CNT films had good uniformity and piezoresistiv-
ity, which implied their application potential as strain gauges in the development of
strain-sensing devices [69].
To further improve mHRM’s capability and equip it with electrical readout, in the
following work, I implemented the CNT deposition method into the design of mHRM
and developed a CNT-based mHRM (CNT-mHRM). In particular, I redesigned the
architecture of mHRM: instead of using two protrusions on doubly-clamped beams as
in mHRM, I adopted a fixed protrusion and a membrane-like PDMS beam to localize
the blood sample (see Figure 4.1a). Using the CNT deposition method I developed
in Chapter 3, I successfully fabricated CNT strain sensor on the force-sensing beam
and captured beam deformation by monitoring the resistance. I characterized the
electromechanical response of the force-sensing beam and optimized the design pa-
rameters, including the concentration of the depositing CNT solution and geometry of
the force-sensing beam. To validate the results generated by CNT-mHRM, I tested
blood samples and conducted measurements based on both resistance and images.
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These two measurements generated consistent results, which confirmed the efficacy
of CNT-mHRM. By performing assays on blood samples treated with pro- and anti-
coagulants, I demonstrated that CNT-mHRM was capable of differentiating blood
samples with different coagulation profiles [70]. The CNT-mHRM devices showed
great potential for point-of-care blood coagulation testing as an in vitro diagnostic
device.
4.2 Experimental section
4.2.1 Preparation of CNT solution
CNT solution was prepared as described in Chapter 3. Briefly, carboxyl-functionalized
multi-walled carbon nanotubes (Cheap Tubes Inc.) were dispersed in deionized water
at a concentration of 5 mg/mL using a probe sonicator (Model VCX130, Sonics & Ma-
terials Inc.). Solutions containing dispersed CNT were then centrifuged at 1000 g for
10 min with resultant supernatants extracted as stock CNT solution for later use [71].
The final CNT concentration in the stock CNT solution was 1.616 ± 0.083 mg/mL
[69].
4.2.2 Device design and fabrication
The CNT-mHRM device was composed of three layers. The CNT strain sensor
resided in the membrane-like, PDMS-made top layer, which was affixed to a rigid
acrylic-made middle layer (Figure 4.1a & b). The bottom layer was designed with a
protrusion on the center, providing a locus to hold the tested blood sample.
The fabrication of mHRM device involved laser cutting acrylic sheet and replica
molding of PDMS. Laser cutting were conducted with a laser cutter system (VLS6.60,
Universal Laser Systems). Cutting patterns were designed in AutoCAD (Autodesk,
Inc.); laser power and cutting speed were determined from the user manual based on
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the thickness of the acrylic sheet with adjustments. Replica molding of PDMS started
with mixing PDMS base with curing agent at certain ratios. The mixture was then
degassed for about 30 min to remove air bubbles before it was poured on the molds.
The molds with PDMS was then degassed again before being baked in 60 ◦C oven
overnight. The cured PDMS was then peeled off from the molds. Base-to- curing
agent ratios of 10:1, 15:1, and 20:1 generated PDMS blocks with Young’s modulus of
1.717± 0.034, 0.615± 0.009, 0.301± 0.009 MPa, respectively, as measured by Instron
tensile testing machine (Illinois Tool Works Inc.).
The middle layer was acrylic shaped by laser cutting. The bottom layer was made
of PDMS by replica molding while the mold was also acrylic shaped by laser cutting.
The mold consisted of two layers: one layer had hollow rectangle structure, and the
other layer had engraved wells. These two layers were cut separately and affixed
together before use (Figure 4.2). PDMS base and curing agent mixture (10:1) were
then poured into the hollow area and excess PDMS were removed using a blade,
before the baking and peel-off step as discussed above.
The top layer featured micropillar arrays to facilitate CNT coating in following
steps. The micropillars were in square shape with 100 µm sides and the gap size
between adjacent pillars was also 100 µm. The top layer was fabricated by PDMS
soft lithography with silicon masters, which were fabricated as described in Chapter
3. Briefly, a silicon wafer was patterned through photolithography and deep reactive
ion etching before it was silanized and spin-coated with PDMS base and curing agent
mixture. Spin coating was conducted at either 400 rpm or 600 rpm for one minute,
generating PDMS membranes with thicknesses of 174.3± 4.37 µm or 105.0± 1.0 µm,
respectively, as measured with a stylus profilometer (Dektak XT, Bruker Corpora-
tion). The spin-coated PDMS was then baked and peeled off as aforementioned.
Ridges were designed along the beam outline, and a scalpel was used to cut out the
beams along the ridges. The length and width of the beams were 15 mm and 2.6 mm
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respectively.
The three layers were assembled by chemically bonding acrylic and PDMS layers.
Briefly, acrylic surfaces was treated with oxygen plasma (Model PDC-001, Harrick
Plasma) for one minute before being immersed in 1% (3-aminopropyl)triethoxysilane
(APTES) for one hour and air dried. The PDMS surface was treated with oxygen
plasma for one minute before being put in contact with the APTES-functionalized
acrylic. The assembly was then baked at 60 ◦C for one hour to assist chemical
bonding [72]. The micropillar arrays were then treated with oxygen plasma for three
minute to turn the PDMS surface hydrophilic before CNT solution, typically with a
volume of 1.5 µL, was dispensed at a corner of the micropillar array and spread over
the micropillar array evenly. The device was then placed in a vacuum chamber to
accelerate water evaporation and minimize CNT aggregation [73].
4.2.3 Device characterization
Devices were characterized to obtain the spring constant and gauge constant (see
Equation 4.1 & 4.3). As shown in Figure 4.3, a probe force transducer (Model 400A,
Aurora Scientific Inc.), which was mounted on a translation stage, was used to mea-
sure the force applied. While the probe was approaching and deforming the beam at
the center, the force applied was recorded from the force transducer and the displace-
ment was recorded from the translation stage. In the meanwhile, a digital multimeter
(Model 34401A, Agilent Technologies) was used to measure the resistance of the CNT
resistor. Conductive grease (Model 846, MG Chemicals) was applied on both ends of
the CNT resistor to minimize contact resistance.
4.2.4 Data acquisition
Multiplex data acquisition in the blood test was achieved by the coordination
between the digital multimeter and an analog switch (Figure 4.1c). The digital mul-
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timeter was connected to a computer via a GPIB Instrument Control Device (Model
GPIB-USB-HS, National Instruments) and controlled by a LabVIEW program. A
multiplexer (CD4051BE, Texas Instruments), controlled by a microcontroller (Ar-
duino Uno, Arduino Company), was used to implement the analog switch circuit.
Switch shifting led to transient connection of different devices to the multimeter for
resistance measurements. Triggering signals were also sent by the microcontroller to
the digital multimeter to synchronize the resistance acquiring and the switch shifting.
The duration of a switch cycle was typically a few seconds depending on the amount
of devices being tested.
A cartridge was designed to house the devices for multiplex testing. Lead wires
were embedded in the cartridge and projected into loading spots for quick device
connection. Images were acquired using a digital microscope (Dino-Lite Handheld
Digital Microscope, AnMo Electronics Co.).
4.2.5 Blood specimen and coagulation assays
Whole blood was collected from human volunteers into a vacutainer (BD Vacu-
tainer, BD Company) containing 3.2% sodium citrate under an IRB protocol approved
by the University of Michigan (HUM00067675: Non-invasive Monitoring of the Crit-
ically Ill and Injured Patient). All blood samples were tested within 4 hours after
blood collection.
For blood samples treated with pro- or anti-coagulants, aprotinin (80 µg/mL;
Sigma-Aldrich Co.) or heparin (8 U/mL; Sigma-Aldrich Co.) were added into blood
and incubated for one hour before assaying with CNT-mHRM devices.
At the beginning of the tests, 20 µL blood sample was suspended between the
protrusion and PDMS beam using a micropipette, before 1.2 µL CaCl2 (0.2 M, Fisher
Scientific) was added into the blood drop with gentle stirring. A petri dish was used to
cover the cartridge to alleviate evaporation before resistance acquisition was started.
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Image acquisition was also started when applicable.
4.2.6 Data analysis
The original data, which was time series of electrical resistance, was smoothed
with a FFT filter using Origin (OriginLab Corp.). The smoothed resistance data
was then converted to clot retraction force following Equation 4.4. To obtain key
coagulation parameters, including reaction time Tr and growth rate GCRF , CRF data
in contraction development phase was fitted to a quadratic function. Specifically,
Tr was defined as the time when CRF started to increase from the baseline level
(CRF = 0) and growth rateGCRF was defined as the CRF growth rate at Tr following
Equation 4.5. Two-sample unpaired Student’s t-test was performed in Origin for
statistical analysis.
An image-processing program was designed and implemented in Python to analyze
beam displacements in the captured videos. Briefly, regions of the beam centers were
selected and the outlines of the beams were analyzed by edge detection to obtain the
displacement of beam centers relative to the original locations. Displacements were
then converted to clot retraction force by multiplying the displacements by the spring
constant (see Equation 4.1).
4.3 Results
4.3.1 CNT-mHRM device design and data acquisition
The CNT-mHRM consisted of three parts: a structure layer and two support
layers (Figure 4.1a & b). The structure layer mainly consisted of a thin PDMS
beam featured with micropillar arrays, made from soft lithography (see Experimental
section). Owing to the capillary action induced by these micropillars, CNT was
uniformly deposited on the PDMS beam [69]. The deposited CNT film possessed
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Figure 4.1:
(a) Schematic of the CNT-mHRM device. The device was assembled
from three parts, with the CNT strain sensor residing on the top PDMS
thin beam. The bottom support layer contained a protrusion that held
the blood sample along with the PDMS beam. Clot retraction force de-
formed the PDMS beam, leading to change in the resistance of the CNT
strain sensor. (b) Photograph of the CNT-mHRM device. (c) Schematic
of the data acquisition setup. The cartridge housed multiple devices, and
the multiplexer (MUX) routed the ohmmeters to the device to be mea-
sured. Microcontroller coordinated the MUX switching and ohmmeter
data acquiring.
good piezoresistivity, making it suitable to serve as a strain sensor. In contact with
the PDMS beam layer is a acrylic block, whose Young’s modulus is about 2 GPa
[74], more than 1000 times stiffer than PDMS. Such high stiffness minimized the
PDMS beam deformation induced by factors other than CRF. The bottom support
layer was designed with an elliptic cylinder protrusion aligned with the center of the
PDMS beam to localize the tested blood sample. The three parts were assembled
through plasma bonding (Figure 4.2).
In the blood testing, a drop of citrated blood, typically with a volume of 20
µL, was suspended between the PDMS beam and the elliptical cylinder protrusion
by pipetting, before CaCl2 solution was added to the suspended blood drop with
gentle mixing. Re-calcification of the blood sample triggered blood coagulation, which
induced clot retraction that pulled the PDMS beam and deformed the CNT film. This
deformation induced change in the resistance of the CNT strain sensor. By monitoring
the resistance of the CNT strain sensor, I could back-calculate the contraction force
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Figure 4.2:
Fabrication process of CNT-mHRM devices. The top layer was fabricated
by photolithography and soft lithography. The resultant PDMS beam
featured with micropillar arrays to assist CNT deposition. Middle layer
was made of acrylic through layer cutting. Bottom layer was fabricated
by PDMS replica molding. The devices were assembled through plasma
bonding.
applied on the PDMS membrane due to clot retraction.
The results of blood coagulation assays are highly dependent on the storage time.
The activity of coagulation factors, including factor VIII and factor IX, are gradu-
ally reduced after blood collection [75]; platelets undergo activation and depletion of
high-energy adenine nucleotide [76]. Thus, high throughput assay is critical to con-
sistent testing results, ensuring that tests are performed within the same time frame
after blood collection. To perform multiplex testing, I designed cartridges which was
capable of housing up to 10 devices, along with a circuit with an analog switch con-
trolled by a microcontroller (Figure 4.1c). The analog switch routed the multimeter
to collect resistance data of a certain CNT-mHRM device at a certain time point.
Thus, multiple tests could be performed simultaneously, which greatly improved the
test throughput.
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Figure 4.3:
Schematic showing the setup of the characterization experiments. A probe
transducer, which is mounted on a translation stage (not shown), displaces
the center of the beam and measures the force applied. The translation
stage records the displacement and a multimeter monitors the resistance.
4.3.2 Device characterization
The contraction force generated by the clot displaces the PDMS beam, leading to
change in the resistance of the CNT strain sensor. I designed experiments to charac-
terize the relationship between resistance change of CNT strain sensor and contraction
force applied on the PDMS beam, as shown in Figure 4.3. In the characterization
experiments, CNT-mHRM devices were fixed on an optical table, and a probe force
sensor, which was mounted on a linear translation stage, approached the center of the
PDMS beam and displaced it. The force, displacement, and resistance were recorded
from the force transducer, translation stage, and multimeter, respectively.
The relationship between the applied force and beam displacement is described
by spring constant, which is defined by
K =
F
∆x
(4.1)
where K is the spring constant, F is the applied force, and ∆x is the displacement. At
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Figure 4.4:
Characterization of CNT-mHRM devices. (a) The applied force plotted
as a function of displacement of the center of the beams, with beams
fabricated using PDMS of different Young’s modulus (MPa) and different
thickness (µm) as indicated. (b) Relative resistance change plotted as
a function of displacement of the center of the beams, with CNT strain
sensor fabricated using CNT solutions of different concentrations as indi-
cated.
a given applied force, smaller spring constant leads to greater displacements and thus
a higher sensitivity. To achieve good sensitivity, low spring constants are desirable.
Classical beam theory predicts that [64]
K =
16Eδ3W
L3
(4.2)
where E is the Young’s modulus, and δ, W , and L are the beam thickness, width,
and length, respectively.
Compared to an ideal beam, beams in CNT-mHRM had more complicated struc-
tures such as the micropillar arrays. Nevertheless, Equation 4.2 implied that K is
dependent on the Young’s modulus of the material and geometry of the beams. Ad-
justing the ratio of PDMS base to curing agent results in cured PDMS with different
Young’s modulus and adjusting the spinning speed during spin coating results in
PDMS beams with varied thickness (see Experimental section).
I first examined the effect of Young’s modulus on the spring constant while main-
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Figure 4.5:
(a) Beam spring constant plotted as a function of PDMS’s Young’s mod-
ulus. Spring constant showed strong linear dependence on Young’s modu-
lus with a Pearson’s correlation coefficient of 0.999. (b) Bar plot of beam
spring constant as a function of beam thickness.
taining the thickness of PDMS beams at 105 µm. Results showed that force ex-
hibited linear dependence on beam displacement, with R2 > 0.99 in linear fittings.
Results also showed that, as expected, beams fabricated using softer PDMS had lower
spring constant. For example, PDMS with Young’s modulus of 1.71, 0.62, and 0.3
MPa generated beams with spring constants of 1.074 ± 0.024, 0.430 ± 0.005, and
0.166 ± 0.005 µN/µm, respectively. The relationship between Young’s modulus and
spring constant showed strong linear correlation, with a Pearson’s correlation coeffi-
cient of 0.999 (see Figure 4.5a).
Beam thickness is the geometric parameter that can be easily adjusted without
redesigning other parts. Thus, I examined the effect of beam thickness on the spring
constant of the resultant PDMS beam. Equation 4.2 predicted that thinner beams
have lower spring constant, which was also observed in our experimental results. As
shown in Figure 4.5b, the spring constant of beams with a thickness of 174 µm was
0.726± 0.014 µN/µm, which was about four times of that of beams with a thickness
of 105 µm, 0.166±0.005 µN/µm. The lowest thickness was limited by the fabrication
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process. When the beam has a thickness lower than 105 µm, it became fragile and
very difficult to manipulate.
Relative resistance change responded to beam displacement in a similar manner.
As displacement increased, relative resistance change increased accordingly in a linear
manner. Similar as spring constant, I define gauge constant (GC) as the ratio of
relative resistance change to displacement, following
GC =
∆R/R0
∆x
(4.3)
where ∆R/R0 is the relative resistance change and ∆x is the displacement.
I characterized the gauge constant of CNT strain sensors deposited using CNT
solutions of three different concentrations, namely 0.81, 1.21, and 1.62 mg/mL. The
gauge constant at the condition of 1.62 mg/mL was 1.07 ± 0.04 mm−1, which was
starkly different compared to that of 0.19 ± 0.01 mm−1 and 0.21 ± 0.01 mm−1 at
the condition of 1.21 mg/mL and 0.81 mg/mL, respectively. The difference between
gauge constants of CNT strain sensors deposited at high concentration and low con-
centration was likely due to the different morphology of the CNT films. As shown in
Figure 3.4, CNT film formed a two-dimensional layer when deposited at 0.81 mg/mL,
while when deposited at 1.62 mg/mL, the film was thicker and resembled a three-
dimensional film. Two-dimensional film and three-dimensional film have been shown
to have different electrical properties [61].
Clot retraction force could be deduced from resistance measurements following
CRF =
∆R
R0
· K
GC
(4.4)
where CRF is clot retraction force, ∆R/R0 is relative resistance change, K is spring
constant, and GC is gauge constant. The ratio of CRF to ∆R/R0, or K/GC, rep-
resents the conversion ratio from relative resistance change to CRF . With a certain
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Figure 4.6:
Comparison of CRF measured from CNT strain sensors image analysis.
(a) Representative micrographs showing the dynamic process of blood
clot formation. Scale bar, 1 mm. (b) CRF plotted as a function of time,
measured from CNT strain sensor and image analysis, respectively. (c)
Bar plots of reaction time Tr, growth rate GCRF , and CRF60 of CRF
dynamics measured with different methods. Data represents mean ±
SEM with n = 3. N.S., P > 0.05.
precision in resistance measurement, the smaller K/GC is, the smaller the minimum
detectable CRF is, and the better the sensitivity is. Thus, low spring constant com-
bined with a high gauge constant generated CNT strain sensors with good sensitivity.
Specifically, I chose beams fabricated from PDMS with a Young’s modulus of 0.30
MPa and a thickness of 105 µm, and CNT strain sensors deposited using CNT so-
lution with a concentration of 1.62 mg/mL. This combination generated CNT strain
sensors with sensitivity of 155.1 µN (per unit resistance change).
4.3.3 Comparison of CNT-mHRM with image analysis
I performed blood coagulation assays using CNT-mHRM devices while simulta-
neously capturing images of the beams, aiming to validate the force measurements
from CNT-mHRM devices. The captured images provided a way to visually monitor
the blood coagulation process as well as to calculate clot retraction force: by analyz-
ing the beam displacements in the images, clot retraction force could be calculated
following Equation 4.1. Clot retraction forces measured from CNT strain sensor were
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calculated following Equation 4.4 using the spring constant and gauge constant that
were characterized.
As expected, CNT-mHRM devices captured dynamic clot retraction (Figure 4.6
a) and revealed two major CRF development phases, namely reaction phase and
contraction development phase (Figure 4.6b), similar as the original mHRM devices
(Figure 2.6 & 2.7) and TEG (Figure 2.8). From the onset of the assay (T = 0)
to the end of reaction phase (T = Tr; designated as reaction time), the coagulation
cascade was in process until fibrin network was formed and activated platelets started
interacting with fibrin and contracting, leading to rapid increase of CRF in the second
phase, contraction development phase. I defined growth rate of CRF GCRF and CRF
at 60 min CRF60 as
GCRF =
dCRF
dT
∣∣∣∣
T=Tr
(4.5)
CRF60 = CRF |T=60 min (4.6)
The reaction time Tr, CRF growth rate GCRF , and CRF at 60 min CRF60 provided
a set of parameters to assess the coagulation profiles.
CNT-mHRM generated results that were close to those calculated from beam
displacements based on image analysis. The reaction time Tr, CRF growth rate GCRF ,
and CRF at 60 min CRF60 from CNT-mHRM measurements were 16.64± 0.71 min,
1.12 ± 0.22 µN/min, and 21.42 ± 2.22 µN, respectively, which were not significantly
different compared to 10.09±2.81 min, 0.79±0.02 µN/min, and 14.43±2.50 µN from
image analysis, respectively. However, relatively large discrepancy between means of
these two measurements were observed. This discrepancy was potentially due to that
in addition to contraction force that bent the beams, clots also applied force that was
tangential to the beam surface, which could have additional effect on the resistance
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Figure 4.7:
Effect of pro- and anti-coagulant on CRF measurements using CNT-
mHRM devices. (a) CRF plotted as a function of time, from baseline,
heparin-treated, and aprotinin-treated blood samples. (b) Bar plots of
reaction time Tr, growth rate GCRF , and CRF60 of CRF dynamics mea-
sured from aprotinin-treated and baseline blood samples. Data represents
mean ± SEM with n = 3. *, P < 0.05. N.S., P > 0.05.
[32].
4.3.4 Effect of pro- and anti-coagulants on clot retraction force
To demonstrate the utility of CNT-mHRM as a diagnostic tool for blood coag-
ulation testing, I conducted experiments using blood samples treated with either
pro-coagulant, namely aprotinin, or anti-cogulant, namely heparin. Aprotinin is an
inhibitor of several serine proteases such as trypsin and plasmin and thus inhibits fib-
rinolysis. It has been used in coronary artery bypass grafting surgery to reduce blood
loss, transfusion need, and end-organ damage due to hypotension [77]. Blood under
the effect of aprotinin has been shown to possess elevated clot retraction force [78].
Heparin is a glycosaminoglycan, which binds to thrombin inhibitor, antithrombin,
and increases its inhibition activity by more than 1000 folds [79]. It has been widely
used as anti-coagulant (blood thinner) to treat and prevent thrombosis. Treatment
of of heparin can greatly inhibit blood coagulation [42].
As shown in Figure 4.7, CNT-mHRM devices captured distinctively different clot
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retraction force dynamics from baseline, aprotinin-treated, and heparin-treated blood
samples. With blood samples treated with heparin, no detectable contraction force
was captured in the assay duration of 60 min, which was consistent with heparin’s
anti- coagulant funtion. Compared to baseline blood samples, aprotinin-treated blood
samples exhibited slight accelerated CRF development and elevated CRF at the end
of the assay (60 min). The reaction time Tr from aprotinin-treated blood samples
was 17.86± 1.75 min, which was significantly less than that of 23.61± 0.28 min from
baseline blood samples. The CRF at 60 min CRF60 were 57.00±11.38 µN, which was
about two folds of that of 26.51± 6.19 µN from baseline blood samples. Though the
growth rates among the aprotinin-treated group and baseline group, which were 1.35±
0.33 µN/min and 0.66 ± 0.12 µN/min, respectively, were not significantly different,
the three parameters combined together showed CNT-mHRM devices’ capability of
differentiating treated blood samples from baseline samples.
4.4 Conclusion
In this chapter, I integrated CNT strain sensors into the mHRM beams and de-
veloped a new device, named CNT-mHRM, for real-time, high throughput blood
coagulation testing. This device consisted of a thin, flexible PDMS beam for force
sensing and a fixed protrusion to localize blood samples. CNT strain sensor was fabri-
cated on top of the PDMS beam which reported the generated blood contraction force
based on the change in the resistance. I characterized the spring constant and gauge
constant of the devices, and performed assays on blood samples. CNT-mHRM gener-
ated measurements that were consistent with those calculated from image analysis. I
further demonstrated the utility of CNT-mHRM by performing assays on blood sam-
ples treated with drugs with known effects. The measurements were consistent with
reported results, which showed the capability of CNT-mHRM of differentiating blood
samples of different conditions. The small size, low cost, and real time measurement
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equipped CNT-mHRM great potential as a point-of-care tool for blood coagulation
testing.
It was also noticed that CNT-mHRM generated results with large variations. A
few factors could have contributed to these variations. First, the fabrication process
involved a few manual steps, such as beam edge cutting and parts alignment, which
inevitably introduced device-to-device variations. By the optimizing the process,
such as replacing manual cutting with laser cutting and adding markers to assist
alignment, the variation in device fabrication would be minimized. Second, in the
current form of CNT-mHRM, the CNT strain sensor is exposed to the environment.
Disturbance from the environment, such as air flowing and temperature fluctuation,
could affect the resistance of the CNT strain sensor [80, 81]. By packaging the CNT
strain sensor with an additional layer, this fluctuation effect could be alleviated.
Future work should be devoted to address these limitations and enhance the strain
sensor performance.
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CHAPTER V
Conclusions, perspectives, and future directions
5.1 Conclusions
Perioperative monitoring of blood coagulation is critical for understanding the
causes of hemorrhage, to guide hemostatic therapies, and to predict the risk of bleed-
ing during consecutive anesthetic or surgical procedures. There is a growing need
to apply technologies to examine blood coagulation. New coagulation diagnostics
that use whole blood samples such as thromboelastography (TEG) are becoming a
standard of care because unlike traditional prothrombin time assays which examine
only the protein portion of blood clotting, TEG utilizes whole blood and can thus
provide a more realistic picture of the interaction between coagulation and inflam-
matory systems. Technologies like TEG provide information on the onset of clotting,
strength of clots formed, and how fast clots lyse. Despite the new value that TEG-like
technologies bring, the mechanics of such devices require a large footprint, are prone
to user error, require large blood volumes, and cannot be used for point-of-care test-
ing. Development of new functional coagulation test platforms which provide similar
information but require less blood, footprint, and operator intervention can disrupt
a growing market and move such blood test system into the home.
This dissertation focuses on developing a platform for blood coagulation assays
with the potential for point-of-care application. Compared to conventional and re-
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cently published microfluidic coagulation assay platforms, the designs in this thesis
aimed to possess greater potential for commercialization and be readily used by clin-
ical professionals in hospitals and even patients at home. Specifically, it possessed
merits including ease of operation, small size, small consumption of blood sample,
low fabrication cost, and high throughput.
In Chapter 2, I designed a miniaturized device to assess blood coagulation func-
tionality by measuring the clot retraction force. Clot retraction force is generated
during blood clotting and it reflects both the functionality of cellular and acellular
components involved in blood coagulation. By measuring this parameter, this de-
vice would capture intrinsic information about coagulation functionality. I adopted
two doubly-clamped beams made from soft materials (polydimethylsiloxane; PDMS)
serving as force sensors, with protrusions at beam centers to hold blood samples.
When the blood sample was suspended between the two protrusions, hydrophobicity
of the beam material and surface tension ensured that the blood sample acquired
a certain shape. This unique design allowed highly reproducible localization of the
blood sample with tiny volume, which was critical for precise measurement. By taking
images of the beams and tracking the location of the fiducial markers on them, the
contraction forces generated were readily deduced. The efficacy of this design was
demonstrated by showing the comparability of the readout with a commercialized
instrument (Thromboelastography) and its capability to differentiate blood samples
treated with anti- or pro- coagulant drugs.
In Chapter 3, I developed a method to incorporate piezoresistive materials into
the beams. The resistance of a piezoresistor changes in response to deformation. By
recording the resistance of the resistors in the beams, the deformation of the beams
and thus the force generated by the clot can be deduced. Consequently, the image
acquisition and processing modules can be removed, which largely simplifies the data
acquisition and processing part of the assay. Coupling of PDMS with electrical con-
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ductors has been a challenge due to the poor adhesion between PDMS and metals.
Carbon nanotube (CNT) has superior conductivity and good compatibility with or-
ganic polymers, and thus great potential to be integrated in soft materials. In this
chapter, I developed a method to deposit CNT on PDMS beams, forming a resistor
that serves as a strain sensor. To obtain a uniform deposition, which is critical for
the reproducibility of the measurement, I fabricated micro-patterns on the beams to
allow uniform spreading of CNT solution on it. The water then evaporates, leaving a
uniform CNT film. This CNT film showed sensitive resistance-strain response, which
was suitable for the application as strain sensors.
In Chapter 4, I applied the CNT deposition in the new design of mHRM devices,
and developed a new device, named CNT-mHRM, which was capable of reporting
clot retraction force based on the CNT strain sensor. The mechanical and electrical
properties of CNT-mHRM devices, namely spring constant and gauge constant, were
characterized for the optimization of the device design. The CNT-mHRM generated
measurements that were consistent with those based on image analysis. The utility
of CNT-mHRM devices were demonstrated by showing the capability of differentiat-
ing blood samples treated with pro- and anti- coagulant. The CNT-mHRM devices
provided real time clot retraction force results from resistance measurements, which
minimized the requirement on data collection setup.
CNT-mHRM devices have low cost, small size, small blood consumption, high
throughput, and little requirement on instrumentation, making it ideal for point-of-
care blood coagulation testing.
5.2 Perspectives and applications
I envision two major applications of CNT-mHRM devices: in clinics as a com-
mercialized point-of-care blood coagulation testing tool and in biomedical research
laboratories as a blood coagulation assessment tool.
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5.2.1 Commercialization
The overall coagulation market is expected to reach 3.58 billion dollars annually
by 2019 [82]. Over 100 million PT and aPTT tests are performed annually. While
current TEG/ROTEM market is not fully determined, it is rapidly gaining accep-
tance in the trauma, sepsis, and cardiovascular surgery markets because of the urgent
need to understand the contribution of platelet function in clotting along with the in-
creased teaching and acknowledgement that traditional PT and aPTT testing are not
adequate to understand the cellular contributions to blood coagulation. A list of med-
ical and surgical entities where coagulation monitoring using the mHRM technology
will be valuable for diagnosis and treatments include but are not limited to: trauma,
sepsis, liver disease, thromboembolic disease (stroke, deep venous thrombosis, pul-
monary embolism), cardiovascular disease and treatment (acute coronary syndrome,
myocardial infarction, cardiomyopathy), and cardiovascular procedures (stents, graft-
ing, cardiovascular assist devices). An increasing number of new oral antithrombotic-
anticoagulation medicines are now available for treatment of conditions such as atrial
fibrillation and thromboembolic diseases in which PT and aPTT testing provide no
value [26]. An increasing body of evidence is demonstrating that whole blood throm-
boelastography (TEG/ROTEM) is capable of providing diagnostic and therapeutic
end-points for a growing number of disease processes and surgical procedures as well
as for monitoring new anticoagulation medicines. Both TEG and ROTEM are FDA
approved for use in the U.S. and CE approved in Europe. Recently, the United King-
dom’s National Institutes for Health and Care Excellence (NICE) which is charge
of providing guidance to enhance health in the UK, recommended use of TEG and
ROTEM to guide transfusion practices and reported its cost effectiveness.
Despite the increasing body of evidence demonstrating value of whole blood co-
agulation testing using TEG/ROTEM, there continue to be barriers to wide spread
adoption. This includes cost (50-60K/device), expensive upkeep, and the need for
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larger sample volumes. This makes the potential for multiplexing (providing spe-
cific batteries of coagulation testing) difficult. It also makes using such technology
in populations like neonates where blood conservation is extremely important diffi-
cult. Operator dependent performance has also been noted including values that can
change between technicians. Lastly, the large size of TEG and ROTEM make their
ability to serve as true POC test very difficult.
In this thesis, I have demonstrated that our technique of whole blood coagulation
testing provides coagulation profiles that are consistent with TEG or ROTEM. Cou-
pled with the design profiled above, our approach is significantly cheaper, requires
less blood volume, and is small enough to provide point-of-care or near point-of-care
service.
I envision developing a commercial product using the razor-razor blade model.
A disposable cartridge containing the mHRM device and non-disposable hardware
components with the required electrical readout system will be developed. The base
customer of our mHRM technology will include hospitals and other health care fa-
cilities where coagulation testing is performed (clinics, hospital wards, ICUs, emer-
gency departments, operating rooms). Another very exciting market that can be
exploited will be point-of-care testing for home use (via visiting nurses and a grow-
ing paramedicine market), pharmacies, etc., which may allow patients and their care
providers to more precisely manage the increasing use of oral platelet inhibitors and
anticoagulants. I believe a significant component of our value proposition is the low
cost, ease of use, and robust nature of the miniaturized mHRM platform. While
our platform is simple, it can easily be expanded to allow for multi-sample testing
as well as coagulation pathway testing (using pre-doped cartridges with a variety of
inhibitors and activators).
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5.2.2 Laboratory use
Given the importance of blood coagulation in clinics, there have been considerable
researches pertaining blood coagulation. In these researches, CNT-mHRM could be
an important instrument for the assessment of coagulation functionality. I envision
the application of CNT-mHRM in the following research topics.
1. The effect of certain physiological conditions on blood coagulation. For exam-
ple, there have been studies on how metastasis affects blood coagulation based
on the hypothesis that circulating tumor cells interplay with platelets during
extravasation [83]. Another example is the study of the effect of hemorrhagic
shock on blood coagulation [84].
2. Developments of new pro-/anti-coagulants [85] and hemostatic therapies. In
such studies, CNT-mHRM could be used to gauge the performance of drugs
and therapies.
3. Mechanistic study of blood coagulation cascade. For example, to study how
deficiency of certain coagulation factors, such as Factor XII [86], affects blood
coagulation profile, CNT- mHRM would be a powerful tool.
5.3 Future research directions
5.3.1 Optimization of device performance
CNT-mHRM devices exhibited noticeable variations in the measurements, which
needs be minimized to achieve better reproducibility and repeatability. These vari-
ations could potentially come from device-to-device variations as well as suboptimal
control over experimental conditions. Future work in the optimization of device per-
formance can be devoted to the following.
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5.3.1.1 Optimization of fabrication process
As discussed in Conclusion section of Chapter 4, the fabrication should be opti-
mized to reduce device-to-device variations in device geometry and CNT strain sensor
performance.
Fabrication process of the PDMS beams can be improved. In the current
process, I used a sharp scalpel to manually cut out the edge of the beams along the
ridges designed on the silicon molds. This process inevitably introduced variation
in the dimensions of the beams. Occasionally, this manual cutting process generated
rough edges, which affected the integrity and the strength of the beams. Laser cutting
is proposed to replace manual cutting as a process with less human intervention. The
challenge in this process would be the alignment of laser beam with the patterns
on the PDMS membrane and the alignment of X-Y axis of the laser system with the
orientation of the PDMS membrane before laser cutting. Creative design of alignment
markers on the PDMS membrane would be helpful in addressing this problem.
Handling of the PDMS membrane can be difficult, since when the membrane is as
thin as 100 µm, it would easily entangle and stick to itself. A potential way to solve
this issue is to place a few drops of ethanol on a petri dish before laying the PDMS
membrane on it. Ethanol’s low surface tension ensures that the PDMS membrane
lays on the petri dish without folding. After the ethanol has evaporated, the PDMS
sticks on the petri dish without serious wrinkles. This method has been tested.
A potential method to enhance the stability of the CNT strain sensor
is to protect the CNT strain sensor from being exposed to the environ-
ment. The resistance of CNT is affected by the temperature and humidity of the
environment [87]. In addition, the disturbance due to air flowing could also poten-
tially affect the resistance. A few methods have been tested though limited success
was achieved. Bonding the top surface of the PDMS beams with another layer of flat
PDMS membrane had been tried. Since both layers were very thin, this process was
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very difficult to operate. Wrinkles were observed on the PDMS membranes, likely
due to the residue stress in the PDMS membranes after bonding. To address this
issue, a creative fabrication or assembling method is needed.
5.3.1.2 Integration of MEMS cantilever beam into PDMS beam as an
alternative to CNT strain gauge
Semiconductor strain gauges have high gauge factors and high strain sensing sen-
sitivity. The fabrication process of MEMS cantilever beams is also well established
[88–90]. By integrating MEMS cantilever beam into the PDMS beam in mHRM, a
more consistent and robust strain sensing could potentially be achieved. The most
challenging part in this method is to transfer the micro structures fabricated on silicon
wafer onto PDMS surface. A reported approach is transfer printing, which requires
a lab-made experimental setup and careful adjustment on the operation parameters
[91].
5.3.1.3 Improvement on the dispersion of CNT in water
Dispersion of nanoparticles in solvent is a research area with intensive studies.
In this thesis, I used carboxyl-functionalized multi-walled CNTs and dispersed them
in deionized water through sonication. Though in-depth study of CNT dispersion in
water is not the focus of this thesis, a detailed process characterization would lead to a
better stability of the CNT/water dispersion and thus a more consistent performance
of the CNT strain sensors. The effect of these parameters on CNT dispersion should
be investigated: CNT functionalization, sonication power and duration, centrifuge
parameters, and storage time of the resultant CNT solutions. The dispersion can be
characterized using a Zetasizer tool, which measures the zeta potential (dispersion
stability) and particle size distribution.
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Figure 5.1:
Design of a scaled-up CNT-mHRM device. Six beams are integrated in a
single device, providing six measurements in each test.
5.3.2 Scale-up
The amount of measurements from a single CNT-mHRM device can be scaled up
by incorporating multiple beams, resembling a six-string guitar (see Figure 5.1). This
scale-up generates multiple measurements and significantly improves the throughput.
The scaled-up device offers the potential for multiplex testing. By pre-treating
the protrusion and/or PDMS beam surfaces with clotting agents, such as kaolin,
heparinase, etc., the device can perform a battery of coagulation testing, providing
coagulation profiles from different aspects.
5.3.3 Further validation
As a proof of concept, this thesis demonstrated the potential of using mHRM de-
vices for point-of-care blood coagulation testing. Further validation will be necessary
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in order to drive mHRM devices to clinics.
Assays using mHRM devices shall be conducted on 70-100 clinical blood samples
of patients with wide range of coagulation profiles. For each sample, 7-10 devices shall
be tested in order to monitor and document the device-to-device variation. TEG or
ROTEM shall be performed simultaneously; these data serve as critical evidences for
validation as well as references for device troubleshooting. Well documented data of
these tests on clinical samples will also provide insights on the correlation between
mHRM measurements and various clinical conditions, which would be useful for future
measurement interpretation.
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APPENDIX A
Fabrication protocols of mHRM devices
A.1 Fabrication of acrylic molds
1. Draw cutting lines in AutoCAD (or other similar modeling software). Two files
are needed. One file is for the bottom and top layer, and the other file is for
the middle layer. Notice that laser cuts out trenches with a width of about 1
mm and normally the resultant shape will be about 1 mm thinner.
2. Laminate a layer of double-sided tape on a 2 mm thick acrylic sheet.
3. Laser cut the acrylic sheet with the AutoCAD files. Cutting speed and power
need to be tested. The laser cutter manuals provide reference values for these
parameters.
4. Adhere the fabricated acrylic molds on petri dishes.
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A.2 Fabrication of the bottom/top layer and the negative
molds for middle layer
1. Thoroughly mix PDMS base with curing agent at a weight ratio of 10:1 and
degas for about 30 minutes.
2. Pour PDMS base-curing agent mixture into the petri dishes with molds. Place
the petri dish in 60 ◦C oven and bake for at least 6 hours.
3. Peel the cured PDMS off the molds and cut with a blade. The resultant parts
out of the molds for bottom/top layer will be used with no further processing.
The parts out of the molds for middle layer will serve as the negative molds for
the middle layer.
A.3 Fabrication of middle layer
1. Treat the negative mold with oxygen plasma for one minute and silanize it for
two hours.
2. Pour PDMS mixture (20:1 base-to-curing agent ratio) on the negative molds.
3. Use a razor blade to scrape on the surface of the negative mold and remove ex-
cess PDMS. A degassing process is conducted if there are noticeable air bubbles
in the PDMS.
4. Bake the PDMS in 60 ◦C oven for 6 hours. This baking time is a critical
parameter.
5. Peel off the cured PDMS from the negative mold.
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A.4 Device Assembling
1. Treat the contacting surfaces of bottom and middle layer with oxygen plasma
for one minute.
2. Align and put the two layers in contact and bake in 60 ◦C oven for five minutes.
3. The top layer is placed on the middle layer before the assay starts. To minimize
water evaporation, a thin layer of PDMS base is applied on the side of the top
layer before it contacts with middle layer.
76
APPENDIX B
Fabrication protocols of CNT-mHRM devices
B.1 Preparation of CNT solutions
1. Weigh 50 mg CNTs using weighing paper and high precision balance.
2. Transfer them into a 15 mL conical tube.
3. Add 10 mL deionized water in the tube and shake gentle.
4. Sonicate the mixture with the probe sonicator at 50% power and 50% duty
cycle for one hour.
5. Centrifuge at 1000 g for 10 minutes.
6. Extract the top 7 mL for use.
B.2 Fabrication and device assembly
1. Fabricate silicon wafer as discussed in Appendix C.
2. Fabricate bottom layers and middle layers using the same principles as discussed
in Appendix A.
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3. Treat the middle layer with oxygen plasma for one minute.
4. Immersed the middle layer 1% (3-Aminopropyl)triethoxysilane (APTES) for
one hour and air-dry it.
5. Treat the bottom layer with oxygen plasma for one hour.
6. Place the two layers in contact and bake at 60 ◦C for five minutes.
7. Spin coat 20:1 PDMS base-curing agent mixture onto the patterned silicon wafer
at 600 RPM for 60 seconds.
8. Bake at 60 ◦C for 6 hours.
9. Peel off the PDMS with pattern facing up.
10. Cut out the outline of the beams using a sharp scalpel along the pre-designed
ridges.
11. Treat the beams with oxygen plasma for three minute.
12. Pipette 1.5 µL CNT solution onto the micropillar array and place them in a
vacuum chamber for one minute.
13. Flip the PDMS beams over and bond them with middle/bottom layer assembly.
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APPENDIX C
Fabrication protocols of microstructures on silicon
wafer
C.1 Fabrication of photomasks
Film photomasks was ordered from companies, with a minimum feature of 10
µm. When smaller feature sizes were required, chrome photomasks needed to be used
instead. The fabrication process of chrome photomasks is described below.
C.1.1 Materials
Glass Mask Plate 5 inches; purchased from LNF store.
(Part Number: LNF0002 ; Mask Plates 5 inches, Soda Lime Glass, 2.29 mm thick,
low reflect chrome, AZ1518 Photoresist.)
C.1.2 Processing
1. Pattern writing on photomasks
Initial mask writing uses Heidelberg µPG 501 Mask Maker, following the stan-
dard operation protocol provided by LNF. The input file of the pattern drawing
79
is in .gds format, which can be generated in the open source software of K Lay-
out. A good practice is to design the structures in AutoCAD, convert the
structures into a few layered regions, and then import the AutoCAD drawing
into K Layout and perform Boolean operations on the regions. Writing time on
the mask maker is normally 30 – 60 minutes.
2. Image reversal and UV exposure (if necessary)
When large areas are designed to be transparent, the mask maker writes re-
verse image on the photomask to minimize the writing time. In this case, an
additional step of image reversal followed by UV flood exposure is performed.
Image reversal uses YES Image Reversal Oven following the standard operation
protocols provided by LNF. Make sure to turn the knob of the gas valve to NH3.
UV exposure uses MA/BA on Flood Exposure mode for three seconds. A test
run using a dummy glass mask is highly recommended.
3. Development
Development uses CEE Developer with the system recipe of AZ726 5X5 SP 40
when image reversal is not conducted and AZ726 5X5 SP 20 IR when image
reversal is conducted.
4. Chrome etching
Chrome etching and mask cleaning uses mask bench with the following pro-
cesses.
(a) Etch the mask in Chromium Etch Tank for two minutes.
(b) Rinse the mask in DI Rinse Tank for two cycles.
(c) Place the mask in Nanostrip for 10 minutes at 60 ◦C. Make sure to warm
up the Nanostrip tank beforehand.
(d) Rinse the mask in DI Rinse Tank for four cycles.
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C.2 Photolithography and reactive ion etching
1. Photoresist deposition
Use ACS200 Cluster Tool with the recipe for thickness of 3.0 µm under the pho-
toresist of SPR 220, following standard operation protocols provided by LNF.
HMDS priming is performed automatically by the tool and no extra cleaning
step is necessary.
2. UV exposure
Use MA/BA with Hard Contact mode and expose for 12 seconds on film pho-
tomask or 10.8 seconds on glass photomask. Detailed operation follows the
standard operation protocols provided by LNF.
3. Development
Use ACS200 Cluster Tool with the recipe of 300 DEV 40s under the entry of
Development.
4. Reactive ion etching
Deep reactive ion etching (DRIE) is performed to etch silicon wafers. DRIE
uses PEGASUS 4 with the recipe of LNF Recipe 1, wherein the etch rate is
about 4.5 µm/min. Since the etch rate fluctuates depending on the condition of
the tool, a two-step etching is recommended when the feature depth is critical.
Underestimate the etch time, run it once, and then measure the depth (see
below). With this measured depth, calculate the actual etching rate. Run the
etching again with additional etching time.
5. Depth measurement
Use Dektak XT following standard operation protocols provided by LNF.
6. Photoresist stripping
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The residue photoresist needs to be stripped after etching.
Photoresist stripping uses YES Plasma Stripper with Recipe 2 following stan-
dard operation protocols provided by LNF. Recipe 2 sets the processing time
as 360 seconds. When extra time is necessary, use Recipe 3 and adjust the
processing time as needed.
This concludes the wafer fabrication.
Alternatively, especially when ACS200 Cluster Tool is offline, photolithography
is performed with standalone spinners and developers as following.
(a) HMDS priming of wafers
Uses YES Image Reversal Oven with Recipe 1. The estimated running
time is 15 minutes.
(b) Photoresist deposition
Uses CEE 200 Spinner following standard operation protocols.
(c) Soft bake
Bake at 115 ◦C for 90 seconds.
(d) Exposure
Same as aforementioned protocol.
(e) Development
Use CEE 200 Developer with recipe 100 mm DP 40-40.
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